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ABSTRACT OF DISSERTATION 
Development of Thymic NK Cells From Double Negative 1                                      
(DN1) Thymocyte Precursors  
by 
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Washington University in St. Louis, 2011 
Professor Wayne M. Yokoyama, Chairperson 
 
 While there has been much progress in defining the specificity and function of 
natural killer (NK) cells, their differentiation has not been fully elucidated.  Previous 
studies of thymocyte development in vitro indicate that double negative (CD4
-
CD8
-
, DN) 
thymocytes can develop into cells with NK cell markers, but these cells have not been 
well characterized.  Moreover, a subpopulation of NK cells which requires an intact 
thymus, i.e, thymic NK cells, has been described with selective expression of CD127 
although their origin and differentiation are also poorly understood.  Herein, we 
generated and characterized NK cells differentiating from thymic DN precursors.  We 
enriched potential progenitors by sorting DN1 (CD44
+
CD25
-
) CD122
-
NK1.1
-
 thymocytes 
from Rag1
-/-
 mice for adoptive transfer into Rag1
-/-
Ly5.1 congenic mice.  Following 
intrathymic injection, donor-derived cells phenotypically resembling thymic CD127
+
 NK 
cells were found in thymus and spleen.  To further characterize these cells, we seeded 
sorted DN1 CD122
-
NK1.1
-
 thymocytes on a confluent monolayer of irradiated OP9 bone 
marrow stromal cells in the presence of IL15, IL7, FMS-like tyrosine kinase 3 ligand 
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(Flt3L) and stem cell factor (SCF).  Flow cytometry results showed NK1.1
+
 cells 
emerged after at least 7 days in culture.  By using limiting dilution analysis, we 
demonstrated a cell frequency of 0.24% (1 out of 414 sorted thymocytes were able to 
generate an NK1.1
+
 cell population).  In vitro differentiated NK cells acquired markers 
associated with the development of conventional bone marrow-derived splenic NK cells, 
but also expressed CD127, which is typically found on thymic NK cells.  In-depth studies 
using gene chip microarrays further confirmed in vitro differentiated NK cells more 
closely resembled thymic NK cells as both expressed novel markers such as CD25 and 
CD103, which were not expressed by splenic NK cells.  Finally, we found that in vitro 
cells generated from thymic precursors secreted cytokines when stimulated and 
degranulated upon target exposure, indicating that they were functional.  Together, these 
data indicate that thymic NK cells can develop from a DN1 progenitor cell and may 
perhaps have a specific role that sets them apart from their splenic counterparts. 
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CHAPTER 1 
INTRODUCTION 
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 Natural killer (NK) cells are a critical component of the innate immune system 
that do not require prior sensitization to be activated upon exposure to tumor or infected 
cells [1].  These cells have been implicated in the priming of T cells, B cell autoimmunity 
and tissue inflammation [2-4].  Unlike cells from the adaptive immune system, which 
take days to weeks to exert their effector function, NK cells can respond in a matter of 
hours [5].  Upon activation, NK cells lyse target cells through the degranulation of 
granzymes and perforin, and also produce cytokines such as interferon- (IFN) and 
tumor necrosis factor-(TNF) [6-9].  Furthermore, NK cells do not require somatic 
rearrangement of genes for expression of their functional receptors, and can be found in 
normal numbers in mice defective in antigen receptor gene rearrangement, such as Rag1
-/-
 
mice [10-12]. While there has been much progress in defining the specificity and function 
of NK cells, their differentiation process has yet to be fully elucidated. 
 
Development of conventional NK cells 
 NK cells are generally thought to be bone marrow (BM)-derived lymphocytes that 
differentiate through the sequential acquisition of markers and functional receptors [8, 
13].  Current NK differentiation models are based on observations made during in vitro 
or in vivo transplantation assays.  Studies have shown that NK cell development, which 
requires an intact BM microenvironment, can be divided into several major steps [14-16].  
First, hematopoietic stem cells (HSCs) commit to the NK lineage, becoming natural killer 
cell precursors (NKPs).  Second, the NKPs acquire receptors and molecules involved in 
target detection, making them immature NK cells (iNKs).  Finally, the iNKs are 
terminally differentiated into mature NK (mNK) cells that have the ability to execute 
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appropriate effector functions.  Thus, NK cells, like other lymphocytes, undergo several 
developmental steps in order to become phenotypically and functionally mature.  
 In greater detail, the earliest step of murine NK cell differentiation in the BM 
involves the commitment of the HSC to the lymphoid linage.  Once this commitment is 
made, HSCs become early lymphoid progenitors (ELP) that can be identified as Lin
-
cKit
high
Sca1
+
Flt3
+
 [14].  At this early developmental stage, the progenitors lose the 
capacity to produce myeloid or erythroid lineages.  Further differentiation of the ELPs 
generates common lymphoid progenitors (CLP) that are Lin
-
cKit
low
Sca1
low
IL7R+ [15]  .  
Shortly thereafter, the acquisition of CD122 (IL2/IL15R) defines the transition from a 
CLP to a committed NKP [16].  The expression of CD122 allows the NKPs to be 
responsive to IL15, which is critical for NK cell development and exerts its effects 
through the IL15R complex, consisting of IL15Rα, IL2/IL15Rβ, and the IL2R common γ 
(γc) chains [17].  In addition, signals received from FMS-like tyrosine kinase 3 ligand 
(Flt3L) and cKit ligand on the BM stromal cells, along with common -dependent 
cytokines influence NK cell commitment since NKPs express CD135 (Flt3) and CD117 
(cKit) [18].  Furthermore, studies where reciprocal BM transfers between lymphotoxin- 
(LT-) and wild type mice showed that close interactions between membrane LT--
expressing NKPs and LT-responsive radioresistant stromal cells are also necessary for 
NK development [19].  Taken together, the generation of NKPs from HSCs not only 
defines the first step in NK cell development, but also suggest that initial commitment to 
the NK lineage is tightly regulated by stromal cells.  
 The maturation of NKP to iNK and later mNK cells can be further characterized 
by several putative intermediate stages (Figure 1), based on correlating marker expression 
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[8, 20].  The generation of CD122-expressing NKPs marks the beginning of intermediate 
stage I while NK1.1, CD94/NKG2 and NKG2D expression defines stage II.  Immature 
NK cells at this stage are comparable to fetal or neonatal murine NK cells that express 
CD94/NKG2 receptors without expressing Ly49 receptors [21].  While the stochastic 
expression of Ly49 receptors follows,  CD94/NKG2 expression is not a prerequisite since 
there are NK cells that are Ly49
+
CD94/NKG2
-
.  During stages III and IV, immature NK 
cells acquire CD117 and integrin 2 (DX5).  At stage IV, NK cells undergo expansion in 
the BM.  After proliferation, iNK cells become mature NK cells characterized by high 
levels of CD11b (Mac1) and CD43.  Hence, with the acquisition of these markers, NK 
cells are terminally differentiated with the capacity to kill targets and produce IFN.  
However, it is important to note that these putative developmental stages are based on 
correlating marker expression in vivo and developmental progression has not been 
directly observed.   
 
In vitro studies with CLP 
 While the in vivo studies have provided some insight into important phenotypic 
changes that occur during cell development, direct experimental observation of marker 
acquisition has been challenging.  In vitro studies showed that NK cells can be generated 
from bone marrow ELPs in the presence of cytokines including stem cell factor (SCF), 
IL7, Flt3L, and IL15 [22-24].  However, the stages through which NK cells differentiate 
in vitro have not been described.  Moreover, cytokines alone are insufficient at generating 
mature NK cells; they require direct contact with stromal cells, such as the OP9 stromal 
cell line, to acquire a mature and functional phenotype [25].  OP9 stromal cells are 
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adherent BM stromal cells that were established from newborn B6xC3H op/op mouse 
calvaria [26].  This stromal cell line has an osteopetrotic mutation in the gene encoding 
macrophage colony stimulating factor (M-CSF).  This mutation favors the differentiation 
of ES cells into hematopoietic cells other than the monocyte-macrophage lineage.  With 
the help of in vitro models, significant progress has been made in discerning some 
cellular and soluble factors provided by stromal cells and progenitors that may be 
instrumental in NK cell differentiation. All things considered, in vivo and in vitro studies 
have provided a framework for considering NK cell commitment, development, and 
maturation.           
 
Bipotential thymic progenitors 
 Although CLP have been shown to directly give rise to NKPs in vivo and in vitro, 
studies have shown that they also have the ability to become bipotential T/NK 
progenitors (T/NKPs) and are found in various fetal organs including blood, thymus, 
spleen, and liver [27-31].  The T/NKPs found in fetal thymus have the ability to generate 
either TCR T cells or NK cells, but no other lineages, when transferred into a thymic 
environment [32].  In vitro studies have indicated that T/NKPs residing in different 
tissues may differentiate in a somewhat different manner than NKPs in the BM.  For 
example, fetal thymus and blood T/NKPs express NK1.1 at later stages of development 
[28, 32], whereas T/NKPs in fetal liver do not up-regulate this specific serological NK 
marker at any stage of development [30].  Taken together, this may suggest that a minor 
progenitor population has the potential to emigrate from the BM to the periphery, thereby 
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differentiating in a different environment which ultimately affects their receptor 
repertoire and perhaps even their function.   
 Furthermore, early studies showed that the earliest thymocyte precursors in adult 
mice also harbor T/NK potential [33].  In these studies, precursors among the double 
negative 1 (DN1; CD44
+
CD25
-
) population were sorted based on their expression or 
absence of CD24, a heat stable antigen, and CD117.  Five distinct populations were 
identified and designated DN1a to DN1e based on the frequency of these two markers.  
DN1a was identified as CD117
+
CD24
-
; DN1b was CD117
+
CD24
low
; DN1c was 
CD117
low
CD24
+
; DN1d was CD117
-
CD24
+
; DN1e was CD117
-
CD24
-
.  Each sorted 
population was cultured on either OP9 stromal cells transfected with delta-like 1 (OP9-
DL1), a Notch receptor ligand, or control non-manipulated OP9 cells.  Results showed 
that DN1c, DN1d and DN1e differentiated into CD4
+
, CD8
+
 or CD4
+
CD8
+
 T cells only 
when seeded on OP9-DL1 cells, while DN1a and DN1b progenitors gave rise to NK1.1
+
 
cells when cultured with control OP9 cells.  The limitation to this study was that the 
NK1.1
+
 population that differentiated in vitro was not further characterized in terms of 
phenotype or function.  Regardless, these studies have demonstrated that a small thymic 
DN1  population in adult mice also harbor T/NK potential.   
 
NK cells beyond the BM 
 While a large population of BM derived mature NK cells are found in the spleen, 
studies have also shown the presence of NKPs and immature NK cells in other 
extramedullary tissues in both adult humans and adult mice.  NKPs in adult humans that 
reside in the lymph nodes (LN) have been shown to traffic from the BM via the blood 
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[34].  Similarly, NKPs and immature NK cells have been detected in murine liver and 
spleen [20, 35].  Although these NKPs and immature NK cells have been shown to 
differentiate in vitro, it is still unknown if they can further differentiate in vivo.  These 
studies suggest that perhaps the BM represents the initial site for HSCs to commit to the 
NK linage, but a small NKP or iNK population can emigrate from the BM and finish 
their maturation elsewhere.    
 Interestingly, the so-called "immature" NK cells in the periphery have been 
shown to be functional, thereby raising the question of whether they truly are immature 
or whether they are NK subsets that differ in phenotype.  For example, fetal hepatic NK 
cells were shown to be NK1.1
+
TRAIL
+
CD11b
low
DX5
-
 but can eliminate tumor cells in a 
TRAIL (TNF-related apoptosis inducing ligand)- dependent manner [35, 36].  
Meanwhile, two distinct subsets of CD122
+
CD3
-
 NK cells within a mouse uterus at mid-
gestations could be identified.  The smaller subset was comparable to splenic NK cells in 
that they expressed NK1.1, DX5, Ly49s and CD43.  However, the larger subset lacked 
the commonly expressed markers of mature NK cells, including NK1.1 and DX5, yet 
expressed NKp46, NKG2D and CD16 [37, 38]. 
 Moreover, an interesting NK subset with phenotypically and functionally distinct 
characteristics was shown to be present in murine thymus by the Di Santo group [39].  
These cells had uniform expression of several NK markers, including CD122, NK1.1, 
DX5, and NKG2D, but were CD127
+
CD69
high
Ly49
low
CD16
-
CD11b
low
.  CD127 is also 
known at the  subunit of the IL7 receptor and is thought to be a good marker for 
activated T cells that have the potential to become long-lived memory cells [40].  IL7R 
is also expressed on naive T cells, which is rapidly lost upon activation, and can also be 
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identified on immature B cells through the early pre-B stage [41, 42] .  The CD127
+
 
thymic NK cells failed to lyse YAC-1 target cells as well as their splenic counterpart, yet 
were more efficient at producing cytokines.  Together, these data suggest the functional 
difference may perhaps be attributed to the unique phenotype such as the low CD11b 
expression and absence of CD16 (FcRIII).   
 Thymic CD127
+
 NK cells are absent in athymic nude mice, indicating that a 
functional thymus is required for their development [39].  However, these cells are not 
only present in Rag1/2-deficient thymus, but also resemble wild type counterparts, 
suggesting that neither more mature thymocytes nor a fully developed thymic medullary 
stromal compartment is required for thymic NK cell homeostasis [13].  Nevertheless, it is 
not known if their progenitors seed the thymus as cells already committed to the NK cell 
lineage or if they differentiate from uncommitted thymic precursors.  While the exact 
progenitor that gives rise to thymic NK cells is not known, recent in vivo experiments 
showed that thymic NK cells do not rearrange the TCR locus, suggesting that they are 
not derived from a committed T cell progenitor [43].  Although these do not arise from 
failed T cell progenitors, their relationship to previously described T/NKP cells has not 
been elucidated.  
 While it is possible that they are generated from T/NKPs, others have suggested 
that thymic CD127
+
 NK cells are recirculating BM derived NK cells that have altered 
their phenotype to serve a precise function within the specific tissue.  Adoptive transfer 
experiments have shown that conventional splenic NK cells can repopulate the spleen, 
liver, and BM of recipient mice [44-46].  However, studies to determine whether these 
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NK cells migrate equally to all tissues or whether the recirculation is selective, have not 
been exhausted. 
 So what are the biological implications of having NK cell subsets residing in 
extramedullary tissues such as the thymus?  For one, the unique phenotype of each NK 
subset may provide a plasticity for NK cell effector function that would allow the cells to 
adapt to different conditions.  Recently, a study showed that conventional NK cells have 
the potential to acquire immunoregulatory function (IL10 secretion) as a consequence of 
extensive activation in visceral leishmaniasis [47].  Furthermore, thymic NK cells have 
been implicated in immunosurveillance due to their lysing of rapidly dividing thymic 
precursors [48].  Whether thymic CD127
+
 NK cells have any other roles such as 
modulation of thymopoiesis, maintaining thymic architecture, or providing a tolerogenic 
function, is still not known. 
 
NK cell subsets in humans 
 The phenotypic and functional differences between thymic CD127
+
 and splenic 
CD127
-
 NK cells from adult mice bear similarities to the different subsets described in 
humans.  Human NK cells comprise approximately 10-15% of circulating lymphocytes 
and can be identified phenotypically by their expression of CD56 [49].  Studies have 
shown that there are two distinct populations of human NK cells: CD56
dim
 (90% of NK 
cells) and CD56
bright
 (10% of NK cells) [50].  The CD56
dim
 subset express higher levels 
of CD16 (FcgRIII) and killer cell Ig-like receptors (KIR), which are similar to mouse 
Ly49 receptors, than their CD56
bright
 counterparts.  While the latter subset is dominantly 
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present in secondary lymphoid tissues (SLT; lymph nodes and tonsils), CD56
dim
 NK cells 
can be found in the BM, blood, and spleen [51]. 
 Developmental ex vivo studies assessing CD16 versus CD94 expression within 
the total CD3
-
CD56
+
 populations of the SLT and blood suggest that human NK cells 
progress from CD94
+
CD16
-
 to CD94
+/-
CD16
+
, marking the final stage of NK cell 
development in vivo [49].  These results suggest CD56
bright
 NK cells, which are 
CD94
+
CD16
-
, differentiate into CD56
dim
 NK cells (CD94
+/-
CD16
+
).  In addition, more 
conclusive studies showed that CD56
bright
 NK cells can further develop into CD56
dim
 by 
culturing these cells with synovial fibroblast in vitro [52].  Although in vitro studies show 
CD56
bright
 NK cells can be further matured, it is not known if this can also occur in vivo.  
Regardless, limitations in human studies have made it difficult to determine the location 
and differentiation process for the CD56
bright
 population.   
 Functional analysis showed that CD56
dim
 NK cells have a natural cytotoxicity, 
while their bright counterpart are more efficient at producing high levels of 
immunoregulatory cytokines [53].  This includes IFN, tumor necrosis factor (TNF), 
granuloctye-macrophage colony stimulating factor (GM-CSF) and IL10.  In addition, 
CD56
bright
 NK cells express a functional CC-chemokine receptor (CCR7) and CD62L, 
suggesting that this subset has the ability to traffic to STL [50].  These differences 
between human NK cells bear resemblance to those found in adult mice.  Based on their 
phenotypic and functional similarities, CD127
+ 
NK cells from adult mice may correspond 
to the CD56
bright
CD16
-
 NK subset.  This perhaps suggests that NK cell heterogeneity may 
be evolutionary conserved and biologically relevant. 
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 Many questions still remain about NK cell development, including the sequential 
acquisition of surface markers as well as the development of NKPs or T/NKPs found in 
the periphery.  In this study, we used adoptive transfer to show that the DN1 CD122
-
NK1.1
-
 thymic population harbors cells that have the potential to differentiate into 
NK1.1
+
 cells that are phenotypically similar to thymic NK cells.  While the number of 
differentiated cells was low in adoptive transfer experiments, we were successful at 
further characterizing these NK cells following in vitro differentiation.  By seeding DN1 
CD122
-
NK1.1
-
 thymocytes on a monolayer of irradiated OP9 cells and adding cytokines, 
we were able to generate NK1.1
+
 cells within 7 days and sequentially follow the 
developmental stages.  Phenotypic, gene chip, and functional analysis studies show that 
the DN1 CD122
-
NK1.1
-
 thymic population generate NK cells that very closely resemble 
freshly isolated thymic NK cells.  These studies should improve our understanding of 
mouse thymic NK cell development, which in turn should aid our knowledge of human 
NK cells. 
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Figure 1.  Developmental stages of NK cells in the BM.  NK cell development  can be 
divided into 5 stages based on phenotypic markers.   NKPs expressing CD122 have been 
shown to give rise to mature NK cells.  Expression of NK1.1, CD94/NKG2, Ly49, and 
cKit define stages II and III.  NK cell expansion and increase effector function occur 
between stages IV and V. 
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MATERIALS AND METHODS 
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Mice 
C57BL/6J (B6), B6.129S7-Rag1
tm1Mom
/J (Rag1
-/-
) Ly5.2, and B6.129S4(C)-Itgae
tm1Cmp
/J 
(CD103
-/-
) mice were purchased from The Jackson Laboratory (Bar Harbor, ME).  Rag1
-/-
 
Ly5.1 congenic mice on the C57BL/6 genetic background were generated by crossing 
B6.SJL-Ptprc
a
 Pep3
b
/BoyJ (Ly5.1) mice with Rag1
-/-
 mice (both from The Jackson 
Laboratory).  CD25Rag1
-/-
 mice were generated by crossing B6.129S4-Il2ra
tm1Dw
/J 
(CD25
-/-
, The Jackson Laboratory) with Rag1
-/-
 mice.  All mice were used between 4 and 
16 weeks of age.  Mice were housed in specific pathogen free conditions and were used 
in accordance with the animal protocol approved by the Animal Studies committee at 
Washington University in Saint Louis.  
 
Antibodies, flow cytometry, and cytokines 
The following antibodies were obtained from BD Biosciences (San Jose, CA): anti-CD44 
(clone IM7); anti-CD25 (PC61); anti-NK1.1 (PK136); anti-CD122 (TM-β1); anti-CD45.1 
(Ly5.1, clone A20); anti-CD45.2 (Ly5.2, clone 104); anti-CD43 (Ly48); anti-CD117 
(2B8); anti-CD62L (MEL-14); anti-B220 (RA3-62); anti-KLRG1 (2F1); anti-Ly49A 
(JR9); anti-Ly49F (HBF-719); anti-Ly49G2 (4D11); and streptavidin PerCP-Cy5.5 (SA-
PerCP-Cy5.5).  The following antibodies were purchased from eBioscience: anti-
Ly49A/D (12A8); anti-Ly49C/I/F/H (14B11); anti-CD49 (DX5); anti-CD11b (M1/70); 
anti-NKG2D (CX5); anti-CD127 (A7R34); anti-CD69 (H1.2F3); anti-CD94 (18d3); anti-
CD16/32 (clone 93); anti-CD103 (2E7); CD86 (GL1); anti-CD45.1 (A20); SA-PerCP-
Cy5.5; anti-KLRG1 (2F1); anti-IFN (XMG1.2); anti-Ly49H (3D10); anti-Ly49I (YLI-
90); and anti-CD107a (eBio1D4B).  Anti-Ly49C (4LO33) was produced from a 
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hybridoma kindly provided by Suzanne Lemieux, Institut National de la Recherche 
Scientifique-Institut Armand- Frappier, Laval, Quebec, Canada).  Anti-Ly49D (4E4) was 
developed in our laboratory as previously described [54].  Surface staining was 
performed on ice in staining buffer (3% FBS, 0.1% NaN3 in PBS).  Nonspecific antibody 
binding was blocked with 2.4G2 (anti-FcγRII/III, American Type Culture Collection, 
Manassas, VA).  All samples were collected on a FACSCanto (BD Biosciences) using 
FACSDiva software (BD Biosciences), and data were analyzed using FlowJo software 
(Tree Star, Inc., Ashland, OR). The following cytokines were purchased from PeproTech 
(Rocky Hill, NJ): IL15, IL7, Flt3L, and IL12.  In addition, we used stem cell factor (SCF, 
Fitzgerald Industries, Concord, MA) and IL18 (R&D Systems, Minneapolis, MN).   
 
Cell sorting 
DN1 CD122
-
NK1.1
-
 cells were sorted from Rag1
-/-
 mice by generation of thymus single 
cell suspensions and stained with a mixture of antibodies that included fluorescein 
isothiocyanate (FITC)-conjugated anti-CD44, phycoerythrin (PE)-conjugated anti-CD25, 
allophycocyanin (APC)-conjugated anti-NK1.1, biotinylated anti-CD122 and PerCP-
Cy5.5 conjugated streptavidin.  Pilot studies showed that Rag1
-/- 
thymus contains only 
CD4
-
CD8
-
 (DN) cells so routine staining for CD4 or CD8 expression was not required.  
Cells were stained in MTHc buffer which contained MTH (308 mOsm solution of 10X 
Hanks Balanced Salt Solution, 1M HEPES and milliQ H2O), 5% v/v FBS and 0.5% v/v 
1mg/ml DNase I stock solution.  Cells were sorted in MTHs buffer which contained 
MTH, 0.5% v/v FBS and 0.5% v/v 1mg/ml DNase I stock solution.  Thymic and splenic 
NK cells were enriched by generation of single cell suspensions from Rag1
–/–
 mice and 
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stained with APC-conjugated anti-NK1.1 in sorting buffer (1% FBS, 0.2% NaN3 in PBS).  
All cells were sorted by flow cytometry to >98% purity on a Dako MoFlo (Beckman 
Coulter) in the Siteman Cancer Center Flow Cytometry Core.  
 
Adoptive transfer 
DN1 CD122
-
NK1.1
-
 cells were sorted from the thymi of 50-80 Rag1
-/-
Ly5.2 mice.  
Highly purified cells were washed several times with PBS to avoid contaminating 
recipient mice with remaining antibodies or FBS.  Approximately 2x10
5
 cells were 
transferred into sub-lethally -irradiated (700cGy) Rag1-/-Ly5.1 congenic mice.  Cell 
suspensions were injected into either the lateral tail vein (IV) or intrathymically (IT) of 
age- and sex-matched recipient mice.  IT recipient mice were given buprenorphine 
hydorchloride for pain every 24 hrs for a period of 72 hrs and were supplied with 
sulfamethoxazole and trimethoprim antibiotics for the duration of the experiment.  All 
experiments were approved by the Animal Studies Committee at Washington University 
in Saint Louis.  
   
Co-culture and resting cells 
OP9 stromal cells (American Tissue Culture Collection) were resuspended in fresh OP9 
media (DMEM, 20% FBS and 1% HEPES) and -irradiated at 2,500 rad.  Cells were then 
seeded at 1.5x10
4
 cell per well in 96-well U-bottom plates and incubated for 20-24 hrs at 
37°C in 5% CO2.  DN1 CD122
-
NK1.1
-
 cells were sorted from the thymi of 10-60 Rag1
-/-
Ly5.2 mice.  Highly purified cells were seeded in wells containing the monolayer of OP9 
cells that were plated the day before.  The co-culture was done in R10 media (RPMI, 
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10% FBS, L-glutamine, 2-ME, and pen/strep) supplemented with IL7 (5 ng/ml), Flt3L 
(5 ng/ml), stem cell factor (SCF, 5 ng/ml) and IL15 (20 ng/ml).  Cells received fresh 
media every 3 days.  Thymocytes were allowed to differentiate anywhere from 4 to 22 
days.  To rest in vitro generated NK cells, we pooled wells with cells after culture for 19 
days, washed them twice with PBS, resuspended them in R10 supplemented with low 
dose IL15 (10 ng/ml) and seeded them at 1-2x10
6
 cells per well in 12 well plates for 36 
hrs.  To rest freshly isolated and sorted splenic and thymic NK cells, we cultured them in 
R10 supplemented with low dose IL15 for a period of 16-20 hrs.  These cells were not 
cultured longer due to lower yield at later time points.  There was no change in 
phenotypic markers or activation during this incubation period.  All cells were incubated 
at 37°C in 5% CO2. 
 
In vitro stimulation assays, intracellular cytokine staining and cytometric bead 
array  
In vitro generated, splenic and thymic NK cells from Rag1
-/-
 mice were stimulated in a 
target cell-free assay.  Briefly, 1 X 10
5
 cells were cultured in either a 96-well plate that 
contained R10 media alone, R10 media with IL12 (10 ng/mL) and IL18 (50 ng/mL), or a 
24 well plate pre-coated with anti-NK1.1 (clone PK136, 10ug/ml; 1.5 hr at 37°C) and 
washed 3 times with PBS.  Cells were incubated at 37°C and 5% CO2 for 1 hr and then 
further incubated in the presence of brefeldin A (GolgiPlug, BD Biosciences) for an 
additional 7 hr. Cells were fixed and permeabilized (Cytofix/Cytoperm; BD) and IFN-γ 
was detected by intracellular cytokine staining and flow cytometry as described 
previously[20].  For the cytometric bead array, cells were stimulated for 8 hrs without the 
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addition of brefeldin A.  At the end of the culture period, we collected the supernatants 
and followed the manufacturer's protocol for the Mouse Inflammation Kit (BD 
Biosciences).  Cytokine secretion was measured with the FACSCalibur using CellQuest 
(BD) and analyzed with the BD CBA Software.  
 
Degranulation assay 
Sorted in vitro generated, splenic and thymic NK cells from Rag1
-/-
 mice were co-
cultured with YAC-1 target cells at varying ratios in 96-well V-bottom plates.  Anti-
CD107a antibody and monensin (eBioscience) were added to each well.  Plates were 
incubated for 2 hr at 37°C, after which surface staining for flow cytometry was 
performed as described above. 
 
Microarray sample preparation and analysis 
NK1.1
+
 cells were sorted from in vitro generated NK1.1
+
 cells along with splenic and 
thymic NK1.1
+
 cells from Rag1
-/-
 mice.  Total RNA was isolated using the QIAGEN 
RNeasy Mini Kit (Valencia, CA) and target synthesis for hybridization to Affymetrix 430 
v2.0 GeneChips was performed with two rounds of linear amplification by the 
Washington University Siteman Cancer Center Microarray Core Facility.  Total RNA 
from 3 different experiments was pooled for target synthesis and three target samples 
were pooled and hybridized to each chip, resulting in three chips for each cell type.  Data 
analysis was performed using Partek® Genomics Suite™ (St. Louis, MO).  The chips 
were normalized and the Bonferroni Correction was applied to correct for multiple test 
samples according to the program instructions. 
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Isolation of lymphocytes from the small intestine 
After euthanizing mice, we performed a midline incision and retracted the skin.  The 
small intestine was cut 0.5 cm below the stomach and 1 cm above the cecum.  The 
intestine was flushed out with 20ml filter sterilized CMF solution (100ml 10X Ca
2+
 and 
Mg
2+
 HBSS + 100ml 10X HEPES-bicarbonate buffer + 20ml FBS + 1L H2O) at 4°C.  
We then cut the intestine longitudinally and laterally into 0.5 cm pieces and rinsed them 
3X with CMF solution.  Intestinal pieces were then placed in a 50ml conical tube with 
CMF/ 10% FBS/ 0.1 mM EDTA solution and stirred for 20 minutes at 37°C at medium 
speed.  After vortexing the intestinal pieces and allowing the bigger particles to settle, we 
transferred the supernatant to another 50 ml conical tube.  We added more CMF/ FBS/ 
EDTA solution to the intestinal pieces and repeated the stirring process.  We combined 
the supernatants, incubated them on ice for 10 minutes, and centrifuged them for 5 
minutes at 1500 rpm at 4°C.  Supernatant was discarded and cells were resuspended in 
R10.  
 
 Isolation of lymphocytes from the large intestine 
After euthanizing mice, we performed a midline incision and retracted the skin.  The 
colon was cut 1 cm below the cecum and near the anus.  The intestine was flushed out 
with RPMI supplemented with Pen/Strep.  We cut the colon longitudinally and laterally 
into 0.5 cm pieces, placed them in a 50ml conical tube with 40 ml prewarmed RPMI/ 
Pen/Strep/ 3% FBS/ 5mM EDTA/ 154mg/ml DL-Dithiotreitol (Sigma), and incubated 
them in a orbital shaker for 20 minutes at 37°C at medium speed.  The contents were then 
strained through a sterile kitchen strainer.  After washing the intestinal pieces 3X with 
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RPMI/ Pen/Strep/ 5mM EDTA solution, we minced them and placed them in a new 50ml 
conical tube with RPMI/ Pen/Step/ 0.155mg/ml liberase (Roche)/ 0.1mg/ml DNase.  
Once again, we placed them in an orbital shaker for 30 minutes at 37°C at medium speed.  
At the end of the incubation, we collected the solution in a 50ml conical tube and mashed 
the intestinal pieces with a syringe plunger.  We washed the pieces with PRMI/ 3% FBS 
3X.  The solution was centrifuged for 10 minutes at 1500 rpm at 4°C, supernatant was 
discarded and cells were resuspended in R10.        
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CHAPTER 3 
IN VIVO DEVELOPMENT OF THYMIC NK CELLS  
FROM DOUBLE NEGATIVE 1 (DN1) PRECURSORS  
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 Most studies done on mouse NK cells focus on the conventional splenic 
population, which are known to develop and mature in the BM.  Unlike their splenic 
counterpart, very little is known about the development of thymic NK cells.  Here, we 
explore the possibility that they develop from progenitors that have seeded the thymus, 
and therefore are not re-circulating conventional NK cells. 
 
Sorting the progenitor population from the thymus of Rag1
-/-
 mice 
 To initiate our experiments, we enriched potential progenitors by sorting a subset 
of double negative (CD4
-
CD8
-
) thymocytes, known as DN1 based on their expression of 
CD44 and low or absent CD25, from Rag1
-/-
 mice (Figure 2).  Presort analysis showed 
that only 4% of thymic lymphocytes were in the DN1 (CD44
+
CD25
-
) stage of 
development.  The majority of the thymocytes were arrested in the DN3 (CD44
+
CD25
-
) 
stage due to the absence of RAG genes that would normally drive the differentiation of 
thymic progenitors into the T cell lineage.  Within the small DN1 
 
population, we 
identified CD122
-
NK1.1
-
 cells, CD122
+
NK1.1
- 
NK precursors, and NK1.1
+
CD122
+
 NK 
cells, which constituted 21%, 11%, and 65% of the cells, respectively.  To study the NK 
cell developmental potential of DN1 cells, we further enriched the population by 
collecting only the CD122
-
NK1.1
-
 cells which represent cells that have yet to commit to 
the NK cell lineage [16].  Since this is the basis for all future experiments, we did a post-
sort analysis which showed that the DN1 CD122
-
NK1.1
-
 thymic population had a 99% 
purity level.  These results suggest there were little to no contaminating mature NK cells 
that could potentially skew our results. 
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In vivo differentiation of NK1.1
+
 cells from thymic DN1 progenitors 
 To assess whether the DN1 CD122
-
NK1.1
-
 population had the potential to 
generate NK cells, we transferred highly purified cells from Rag1
-/-
 Ly5.2 mice into sub-
lethally irradiated Rag1
-/-
 Ly5.1 congenic recipients.  Cells were adoptively transferred 
either intravenously (IV) or intrathymically (IT).  Thirty two days post transfer, we 
analyzed the spleen and thymus of recipient mice for donor-derived NK1.1
+
 cells (Figure 
3).  In mice that received IV transferred cells, a small number of splenic NK cells were 
donor-derived (Ly5.2
+
), while the thymus was completely devoid of such cells.  On the 
other hand, a larger pool of donor-derived cells was present in mice receiving the sorted 
progenitors intrathymically, where approximately 50% of the thymic NK cells were 
derived from Ly5.2
+
 donor cells.  In addition, NK cells generated from these donor 
thymocytes were also detected in the spleen of the same mice where they constituted 
close to 6% of all NK cells. These results suggest that, upon intrathymic adoptive 
transfer, the DN1 CD122
-
NK1.1
-
 thymic subpopulation can differentiate into NK1.1
+
 
cells in the thymus and that a small percent of these NK cells has the potential to 
emigrate to the spleen. 
 
In vivo differentiation of thymic DN1 cells generates non-conventional NK cells 
 While the number of donor cells in recipient mice receiving IV transferred DN1 
CD122
-
NK1.1
-
 thymocytes was too low for analysis, we were able to further characterize 
the NK cells generated from donor cells transferred intrathymically (Figure 4).  By gating 
on NK1.1
+
 cells in the thymus, we found analyzed informative markers associated with 
thymic and splenic NK cells.  Although the staining patterns for each marker were 
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somewhat different, i.e., some markers were expressed on all cells while others were 
expressed on subsets, we used the percent of positive cells (above isotype control 
staining) as a convenient (although technically imprecise) means to compare and describe 
the various staining profiles.  With this approach, we found that IT transferred 
NK1.1
+
Ly5.2
+
 cells in the thymus expressed the thymic marker CD127, similar to thymic 
NK cells from unmanipulated  mice, albeit at somewhat lower levels for unclear reasons.  
In addition, we found CD25 to be selectively expressed by thymic NK cells in both 
control and IT mice.  This was a surprising finding since previous studies did not note 
CD25 expression on thymic NK cells in C57BL/6 mice [39, 55].  This marker may be 
related to the origin of our NK cells from Rag1
-/-
 mice since we also did not find it 
expressed on thymic NK cells from C57BL/6 mice (data not shown)  Regardless, 
unmanipulated splenic NK1.1
+
 cells do not express either receptor, while thymic NK1.1
+
 
cells from both unmanipulated and IT mice had CD25
low
 and CD25
high
 populations, the 
latter usually falling outside the range of detection.  The CD25
high
 staining was unlikely 
due to non-specific Fc receptor staining because splenic Rag1
-/-
 cells which contain an 
abundant number of FcR-bearing cells did not stain.  For Ly49 expression, due to the low 
return yield of Ly5.2
+
 NK cells in the IT mice, we were unable to assess the expression of 
the individual Ly49 molecules, thus pan-Ly49 antibodies were used to detect 
Ly49C/I/F/H and Ly49A/D.  Similar to thymic NK cells from unmanipulated mice, a 
sizable fraction of donor NK1.1
+
Ly5.2
+
 cells in the thymus were Ly49
low
, whereas a 
smaller fraction expressed Ly49 receptors at higher levels.  However, essentially all 
splenic NK cells from control mice were Ly49
high
.  Finally, we were able to detect DX5 
and CD11b on donor-derived cells in the thymus, although their expression level was 
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lower than on unmanipulated thymic NK cells.  Thus, these data suggest that IT 
transferred DN1 CD122
-
NK1.1
-
 cells can differentiate into cells that resemble thymic NK 
cells. 
 In the spleen, donor NK1.1
+
Ly5.2
+
 cells had a phenotype consistent with that of 
donor and control NK cells in the thymus (Figure 4).  Similar to unmanipulated thymic 
NK cells, NK1.1
+
Ly5.2
+
 cells found in the spleen expressed CD127 and CD25, although 
at much lower levels.  In addition, they expressed both Ly49
low
 and Ly49
high
 and were 
CD11b
low
.  This phenotype was distinct from control splenic NK cells, suggesting that the 
adoptive transferred progenitor cells differentiate into thymic NK cells which can then 
emigrate to the periphery.   
 
Discussion 
   Conventional NK cells found in the periphery, particularly in the spleen, have 
been shown to develop from progenitors in the BM [8, 16].  On the contrary, the 
identification of the specific progenitor and developmental site that generates thymic NK 
cells has been challenging.  To date, there are speculations on whether these unique NK 
cells begin their life as T/NK bipotential progenitors that initiate their development in the 
thymus, or whether they are re-circulating conventional NK cells that have altered their 
phenotype based on their environment.  While studies have shown that T/NK bipotential 
progenitors found within the DN1 population in the thymus are responsible for generating 
NK cells in vitro [33], it has yet to be shown whether they differentiate into thymic NK 
cells in particular.  Moreover, these studies showed that it was the DN1 CD117
+
 cells that 
generated NK1.1
+
 cells upon culturing them with OP9 cells.  One major caveat to these 
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experiments is that they failed to exclude NK1.1
+
 cells that are within this population.  In 
our hands, approximately 5% of the DN1 CD117
+
 population in Rag1
-/- 
mice were 
CD122
+
NK1.1
+  
(data not shown).  This small pool of NK cells was also found in 
C57BL/6 mice.  Our results suggest that there was a contaminating population of NK 
cells in early experiments.  Since only 1.5% of DN1 cells expressed CD117, we chose to 
collect all cells within the DN1 population, excluding CD122
+
NK1.1
-
 and 
CD122
+
NK1.1
+
 cells.  This not only increased our recovery yield, it also included cells 
that were CD117
+
, approximately 3% of DN1 CD122
-
NK1.1
-
 cells. 
 To address the question of whether this population differentiated into thymic NK 
cells, we adoptively transferred 2x10
5
 highly purified DN1 CD122
-
NK1.1
-
 cells from 
Rag1
-/-
Ly5.2 mice into sub-lethally irradiated congenic mice.  Pilot studies where we 
transferred less cells or used non-irradiated hosts yielded negative results as we could not 
find the Ly5.2
+
 cells (data not shown).  Perhaps this may indicate that these thymocytes 
needed "space" in a niche created by irradiation.  Furthermore, harvesting the cells at 
earlier time points proved to be difficult since there were too few Ly5.2
+
 cells to analyze 
(data not shown).  Results from these pilot experiments suggest an appropriate progenitor 
number, space, and time were essential to our in vivo studies.  
 Using these guidelines, we were able to characterize donor-derived cells that had 
differentiated in vivo for 32 days.  Interestingly, we detected a Ly5.2 and Ly5.1 double 
positive population in the spleen of the IT mice.  This may be due to discrepancies in the 
staining process, but considering the absence of this double positive population in the 
thymus, it is highly unlikely.  A second explanation may be that there are more 
dead/dying cells in the spleen, thus appearing as double positive.  Yet a third explanation 
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is that the donor cells acquired the Ly5.1 molecule from recipient cells found in the 
spleen.  This could be likely since NK cells have been shown to acquire MHC class I 
molecules from target cells by stripping them from the cell's membrane [56, 57].   
 A second interesting finding was the expression level of most phenotypic markers 
in both thymic and splenic NK1.1
+
Ly5.2
+
 cells.  Similar to unmanipulated thymic cells, 
the thymic donor-derived IT cells were CD127
+
, DX5
+
, and CD11b
low
, although their 
expression level (MFI) was much lower.  These results suggest that one or more factors, 
such as stromal cells, that aid in differentiation and may be necessary for marker 
expression was affected when the mice were irradiated, also explaining why our NK 
numbers were much lower than those in unmanipulated mice.  In addition, DX5 
expression in splenic donor-derived IT cells was also detected at much lower levels, once 
again supporting our idea that the process of irradiating the mice leads to some 
unforeseen changes that may affect marker repertoire.  Furthermore, although CD127 and 
CD25 were expressed on splenic NK1.1
+
Ly5.2
+
 cells from IT transferred mice indicating 
some similarity to unmanipulated thymic NK cells, their expression was not much higher 
than the isotype control.  This could indicate one of two things: 1)  DN1 CD122
-
NK1.1
-
 
cells initiate their developmental process in the thymus, allowing for the expression of 
CD127, CD25, and Ly49
low
 receptors, but emigrate to the periphery to continue their 
maturation, which includes the down-regulation of CD127 and CD25.  2) DN1 CD122
-
NK1.1
- 
progenitors fully develop in the thymus, but retain the capacity to alter their 
receptor repertoire according to their environment, as seen by the emerging Ly49
high
 
population.  Whereas both possibilities are plausible, it will be difficult to verify these 
speculations without further knowledge of their in vivo differentiation process.   
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 While further in vivo studies need to be done, we were able to show that the DN1 
population harbors cells with the potential to differentiate into thymic NK cells.  This 
suggest CD127
+
 NK cells are not recirculating conventional BM-derived NK cells.  
Though the majority of these cells developed and resided in the thymus, a small pool had 
the potential to emigrate into the periphery.  These results further validate the idea that 
not all NK cells develop in the BM, more specifically, that CD127
+
 NK cells develop in 
the thymus. 
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Figure 2.  Sorting DN1 CD122
-
NK1.1
-
 cells from Rag1
-/-
 mice yields a highly 
enriched progenitor population.  Thymi from 10 Rag1
-/- 
mice were removed and cell 
suspensions were made.  Cells were labeled with anti-CD44, anti-CD25, anti-NK1.1 and 
anti-CD122 and sorted using the Dako MoFlo.   Presort analysis shows cells were gated 
on lymphocytes based on the forward/side scatter profile.  Approximately 2x10
4
 DN1 
CD122
-
NK1.1
-
 cells were used in a post sort analysis.  Data represents more than two 
experiments.  
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Figure 3.  Donor derived DN1 CD122
-
NK1.1
- 
 thymocytes differentiate into NK1.1
+
 
cells in the thymus.  Thymi from Rag1
-/-
 Ly5.2 mice were harvested and sorted based on 
DN1 CD122
-
NK1.1
-
 phenotype as shown in Figure 2.  Cells were transferred into 
irradiated Rag1
-/-
 Ly5.1 mice either intravenous (IV) or intrathymically (IT).  Irradiated 
littermates were used as controls.  Cells were harvested from the spleen and  thymus 32 
days post-transfer.  NK1.1
+
 cells from the lymphocyte population were then examined for 
host (Ly5.1
+
) and donor (Ly5.2
+
) cells.  Data are representative of two experiments. 
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Figure 4.  DN1 CD122
-
NK1.1
- 
 thymocytes differentiate into NK cells with a unique 
phenotype.  DN1 CD122
-
NK1.1
- 
 thymocytes from Rag1
-/-
 Ly5.2 mice were transferred 
into irradiated Rag1
-/-
 Ly5.1 mice intrathymically (IT).  Donor (Ly5.2
+
) NK cells from IT 
mice were compared to NK cells from unmanipulated (non-irradiated) littermates 32 days 
post transfer.  Gray-filled histograms represent cells stained with an isotype control and 
blue-line histograms represent cells stained with the indicated antibody.   Data are 
representative of two experiments. 
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CHAPTER 4 
IN VITRO DEVELOPMENT OF THYMIC NK CELLS 
FROM DN1 CD122
-
NK1.1
-
 THYMOCYTES 
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 Early studies performed by T cell biologists showed that when DN1 cells were 
cultured with OP9 stromal cells transfected with Delta-like 1, T cell markers were 
detected on developing cells by day 6.  When this same population was cultured with 
control OP9 cells, the emerging cells expressed NK1.1 [33].  The limitation to this 
significant finding was the lack of any further characterization of these NK1.1
+
 cells in 
terms of phenotype or function.   Here, we aimed to determine whether in vitro generated 
cells that differentiate from DN1 cells resemble thymic or conventional splenic NK cells 
and whether these cells were functional.    
 
In vitro differentiation of NK1.1
+
 cells from thymic DN1 progenitors  
 Due to low donor-derived NK cell numbers in adoptive transfer experiments, we 
were unable to perform more detailed experiments with this approach.  To further 
examine the events that take place during NK differentiation of the putative thymic 
progenitors, we instead utilized an in vitro system in which thymic progenitors were co-
cultured with OP9 stromal cells in the presence of cytokines.  Sorted DN1 CD122
-
NK1.1
- 
thymocytes from Rag1
-/-
 mice were seeded onto a confluent monolayer of irradiated OP9 
stromal cells and cultured in IL7, Flt3L, SCF, and IL15.  At different time points, we 
visually and microscopically examined wells for growth (Figure 5).  After 10 days of co-
culture, we visualized a colony of cells at the center of most wells, but by day 16 cells 
appeared in areas devoid of the OP9 monolayer.  To assess whether these cells had 
differentiated after 19 days in culture, we pooled growth-positive wells identified by 
visual inspection and analyzed surface expression of NK1.1 via flow cytometry.  Results 
showed that by day 16, most cells were NK1.1
+
 (Figure 6A).  Kinetic analysis showed the 
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absence of NK1.1
+
 cells on day 4 but NK1.1
+
 cells were readily detected on day 7, and 
continued to increase on day 10 (Figure 6B) .  Thereafter, the percentage of NK1.1
+
 cells 
was relatively stable.  CD122 expression paralleled that of NK1.1 expression.  Together, 
these results suggest that DN1 CD122
-
NK1.1
-
 thymocytes contained progenitors capable 
of developing into NK1.1
+
 cells in an in vitro system with OP9 stromal cells and 
cytokines.  
 
Precursor frequency of the DN1 population 
 To determine the frequency at which an NK1.1
+
 cell was differentiated, we 
performed a limiting dilution analysis.  Sorted Rag1
-/-
 DN1 CD122
-
NK1.1
-
 thymocytes 
were seeded in wells at different cell densities in 24-well replicates.  After 19 days, all 
growth-positive wells were individually collected and cells were surface stained and 
analyzed via flow cytometry.  Dead or dying cells were excluded with propidium iodide 
(PI) staining.  Results showed that approximately 80-90% of the cells in all growth-
positive wells were NK1.1
+
.  Although the level of NK1.1 expression was somewhat 
variable, the NK1.1 mean fluorescent intensity (MFI) was independent of seeding dose 
(Figure 7A).  For example, cells seeded at 300 cells/well expressed higher levels (MFI) of 
NK1.1 compared to cells seeded at 400 and 500 cell/well.  In addition, when all growth- 
positive wells from one seeding dose were compared to each other, expression level of 
NK1.1 varied from well to well (Figure 7B).  This data suggest that we could use the 
frequency of wells with NK1.1
+
 cells, regardless of the level of NK1.1 expression, as a 
reliable outcome in limiting dilution analysis.  If we assume that the cells being titrated 
are randomly and independently distributed among all wells, then the number of cells that 
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differentiated into NK1.1
+
 cells found in each well should follow the Poisson distribution.  
By graphing the number of cells per well versus the log of the frequency of negative 
cultures, we were able to demonstrate a frequency of 0.24% with a 95% confidence 
interval of 0.3% to 17% (Table I and Figure 8).  These results indicate that one out of 
every 416 sorted DN1 CD122
-
NK1.1
-
 thymocytes from Rag1
-/-
 mice is an NK cell 
precursor that can differentiate into and NK1.1
+
 cell in vitro.  
 
In vitro generated NK1.1
+
 cells have a unique phenotype 
 In vivo studies have delineated tentative developmental stages for conventional 
splenic NK cells based on marker correlation but developing NK cells have not been 
directly observed to undergo the putative phenotypic changes that characterize each stage 
[16, 20].  Here, we were able to directly follow the kinetics of NK cell development from 
progenitor stage to NK1.1-expressing cells.  Briefly, sorted Rag1
-/-
 thymocytes were 
seeded at a concentration of 1000 cells per well on a monolayer of irradiated OP9 stromal 
cells in the presence of cytokines.  At different time points, equal number of wells were 
pooled, stained with a panel of antibodies and analyzed via six-color flow cytometry.  We 
used a seeding concentration of 1000 cells per well to insure that each well would have 
differentiating NK1.1
+
 cells (from an average of 1-2 progenitors) and chose to pool wells 
for analysis due to the small number of cells available.  Again, as described for the 
intrathymic transfer studies, the staining patterns for each marker were somewhat 
different but we used the percent of positive cells (above isotype control staining) as a 
convenient (although imprecise) means to compare and describe the various staining 
profiles.  Phenotypic analysis of the developing cells after 4 days of co-culture showed 
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most markers were absent, except CD117 (cKit) and CD25 (IL2R) which were 
expressed at low levels (Figure 9).  Although the cells lacked most markers on day 4, 
including NK1.1 and CD122 (Figures 6, 9A), more than 30% had differentiated into 
NK1.1 expressing cells by day 7, all of which co-expressed CD122.  The number of 
NK1.1
+
 cells increased to more than 85% by day 19 (Figures 6, 9B).  Taken together, 
these data strongly suggest that the cells were differentiating into NK1.1
+
 cells rather than 
representing outgrowth of contaminating mature NK cells because NK1.1 was not 
initially expressed and markers associated with NK cells were primarily expressed only 
after a week of in vivo culture. 
 To further analyze the kinetics of development in the in vitro generated cells, we 
compared the phenotypic results on NK1.1
+
 cells from different culture time points to 
each other, expressed as a percentage of NK1.1
+
 cells (Figure 10).  As compared to other 
markers, both CD122 and NK1.1 were expressed relatively early with ready detection on 
day 7, where approximately 30% of total cells express both markers (Figures 6, 9A).  
Interestingly, CD44 was present throughout the entire culture time, with more than 99% 
of the cells expressing it (Figure 10).  Developing cells also failed to express CD94 on 
day 4, but more than 80% of NK1.1
+
 cells had up-regulated this receptor by day 7.  By 
contrast, NKG2D was poorly expressed on day  7, and instead was expressed by 
essentially all NK cells on day 10.  The acquisition of CD94 and NKG2D on developing 
NK cells after CD122 and NK1.1 are expressed supports previous findings by other 
colleagues [8, 20, 21].  With the acquisition of NKG2D on day 10, followed by the 
subsequent expression of Ly49 on day 13, it appeared that the in vitro generated NK cells 
progressed from stage II of development to sate III during this window of time.  Again, 
41 
 
limited by the number of cells, we were unable to assess specific Ly49 expression with 
mono-specific anti-Ly49 antibodies during this temporal analysis.  Only a fraction of the 
cells expressed Ly49s.  However, unlike conventional splenic NK cells, the in vitro 
generated cells lacked DX5 expression, and CD43 and CD11b were detected only after 
about 16 days in culture.  Interestingly, low levels of CD127 was detected on the in vitro 
cultured NK cells.  While 10% to 25% of the cells were CD127
low
 on day 10, there were 
more than 50% NK1.1
+
CD127
+
 cells by day 19 (Figures 9, 10).  Overall, these studies 
have allowed us to follow the sequential development of putative NK cells from DN1 
thymocytes which generally recapitulates developmental stages of developing NK cells in 
the BM. 
 
Comparison between in vitro generated cells and freshly isolated NK cells 
 Our studies on the kinetics of development suggested that in vitro generated 
NK1.1
+
 cells were either conventional NK cells arrested between stage II and stage IV of 
the developmental process or that they differentiated into NK1.1
+
 cells resembling thymic 
NK cells.  Inasmuch as our adoptive transfer studies suggested that the sorted DN1 cells 
gave rise to NK1.1
+
 cells that more closely resembled thymic NK cells, we sought to 
further determine if our in vitro differentiated NK1.1
+
 cells resembled thymic NK cells.  
Here, we compared expression of surface markers on in vitro derived NK1.1
+
 cells after 
19 days in culture with that of freshly isolated thymic and splenic NK cells (Figure 11).  
Similar to thymic CD127
+
 NK cells, less than half of the in vitro generated cells had low 
expression of Ly49 receptors, CD11b, and CD62L.  Further detailed analysis of the Ly49 
receptors confirmed these data because splenic NK cells readily expressed Ly49A, 
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Ly49C, Ly49D, Ly49G2, and Ly49H, some of which are expressed on >50% of cells.  
On the contrary, while the largest pool of thymic NK cells expressed Ly49G2,  less than 
20% expressed any other of these receptors,  (Figure 12).  In vitro generated cells lacked 
Ly49C and Ly49G2 and less than 10% expressed low levels of Ly49A, Ly49D, Ly49F, 
or Ly49H (Figure 12).  Kinetic analysis showed that CD25 was up-regulated in enriched 
thymic progenitors during the first 4 days of culture and expression was then constant 
through day 19 (Figures 9, 10).  Surprisingly, as noted above (Figure 4), CD25 was also 
detected in thymic NK cells from Rag1
-/-
 mice with essentially all cells expressing it at 
intermediate to high levels (Figure 11).  Studies done on splenic and thymic NK cells 
from C57BL/6 mice showed CD25 was not present on either NK cell type, suggesting 
CD25 is selectively expressed on thymic cells from Rag1
-/-
 mice (data not shown).  
Finally, and most importantly, the majority of in vitro generated NK cells uniformly 
expressed CD127, a marker of thymic NK cells [39], albeit at lower levels than thymic 
NK cells.  Overall, the phenotypic comparisons between all three cells types suggest that 
in vitro generated NK1.1
+
 cells more closely resemble thymic, and not conventional 
splenic NK cells.   
 Unlike thymic NK cells, the in vitro NK1.1
+
 cells did not express the integrin 
DX5 or CD69.  However, a slight modification in the culture protocol was informative.  
Briefly, thymic progenitors were allowed to differentiate into NK1.1-expressing cells for 
19 days under standard culture conditions with OP9 cells and cytokines, at which point 
cells were harvested, washed, and incubated in low-dose (LD) IL15 alone for 36 hrs.  
Interestingly, culture in LD IL15 alone was associated with the up-regulation of DX5 and 
CD69 and the down-regulation of CD11b (Figure 13), resulting in a phenotype strikingly 
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similar to thymic NK cells (Figure 11).  Thus, this modification resulted in in vitro 
differentiated NK cells that now very closely resembled thymic NK cells. 
 
In vitro generated cells are functional 
 Due to phenotypic similarity to thymic NK cells, we further sought to characterize 
the in vitro generated NK1.1
+
 cells by comparing their function to freshly isolated thymic 
NK cells.  Functional analysis for the production and secretion of cytokines, along with 
the ability to degranulate were assessed by both target cell-free and cell-dependent 
stimulation assays, respectively.  For these studies, we used in vitro differentiated NK 
cells cultured under standard conditions with OP9 cells and cytokines for 19 days.  
Cytometric Bead Array (CBA) results showed that at this point, the cells were secreting 
several cytokines and chemokines, including monocyte chemotactic protein-1 (MCP-1), 
IFN, TNF, and IL6, without further stimulation (Figure 14).  These results suggest that 
the in vitro NK1.1
+
 cells were in a pre-activated state due to their culturing environment, 
thus making them incomparable to freshly isolated splenic and thymic NK cells.   
 To address this, we differentiated Rag1
-/-
 DN1 CD122
-
NK1.1
-
 thymocytes in 
standard culture conditions for 19 days, at which point, cells were collected, washed and 
"rested" in low-dose (LD) IL15 alone.  Every 12 hours, we pooled cells and re-cultured 
them in either media alone (non-stimulated) or media supplemented with IL12+IL18 for a 
period of eight hours.  Results showed that in vitro generated cells reached a state of 
"rest" only after being in the LD IL15 culture for 36 hours, at which point they ceased to 
secrete all tested cytokines (Figure 15 and data no shown).  In addition, cells did not lose 
the ability to secrete certain cytokines upon IL12+IL18 stimulation at any time point, 
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even after reaching their resting state.  Finally, once removed from their standard 
culturing conditions and placed in LD IL15 alone, cells altered their phenotype to further 
resemble thymic NK cells more closely (Figure 13).  Together, these results suggest that 
subtle changes in culture may resemble, but not necessarily recapitulate, the dynamically 
changing environment that occurs during in vivo cell development. 
 To assess whether the resting in vitro generated NK cells were functional, we 
performed a target cell-free stimulation assay with IL12+IL8 or plate bound anti-NK1.1 
(clone PK136) for 8 hours.  Intracellular flow cytometry results were compared to those 
from sorted splenic and thymic NK cells that were cultured in LD IL15 for 16 hours 
(Figure 16).  These in vivo differentiated NK cells were not cultured (rested) longer due 
to a lower yield at later time points.  Pilot studies showed there were no changes in 
phenotypic markers or activation during this incubation period (data not shown).  While 
the majority of cells, regardless of in vivo or in vitro differentiation, produced a large 
amount of IFN when stimulated with IL12+IL18, less than 30% were capable of 
responding to PK136 (Figure 16).  Moreover, the amount of IFN detected in PK136 
cultures was approximately one log lower than that produced when stimulated with 
IL12+IL18.  These results suggest that the in vitro generated NK cells are functional and 
can be stimulated to produce IFN, especially when stimulated in an ITAM-independent 
manner. 
 To more broadly compare the function of LD IL15 rested in vitro differentiated 
NK1.1
+
 cells to rested splenic and thymic NK cells, we once again used a mouse 
inflammation CBA to quantitatively detect a wider panel  of secreted cytokines.  As 
expected from the intracellular staining assay, all cell types secreted a large amount of 
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IFN when stimulated with IL12+IL18, but only the latter responded as well, if not better, 
upon PK136 stimulation.  Interestingly, TNF was produced by thymic and in vitro NK 
cells upon stimulation with both IL12+IL18 and PK136, whereas splenic NK cells 
produced TNF only with PK136 stimulation.  IL6 was detected only after  IL12+IL18 
stimulation but MCP-1 was not detected at any point (Figure 17).  These results further 
indicate that the in vitro generated NK cells can be activated with various stimuli to 
functionally resemble thymic NK cells.  
 Finally, to determine if the in vitro generated NK cells were capable of 
responding to target cells, we co-incubated the three cell types with YAC-1 target cells.  
In a similar manner, thymic and in vitro NK cells degranulated upon target encounter 
(Figure 18).  While there was a difference in degranulation between splenic NK cells and 
thymic and in vitro NK cells, it may not be biologically significant.  Overall, phenotypic 
and functional analysis show the similarities between thymic and in vitro generated NK 
cells, and together they share differences from their splenic counterpart. 
 
Discussion 
 Adoptive transfer studies showed thymic CD127
+
 NK cells developed from DN1 
CD122
-
NK1.1
-
 progenitors, although further analysis was limited due to the low recovery 
yield of Ly5.2
+
NK1.1
+
 cells 32 days post transfer.  To compensate for the experimental 
limitations imposed by in vivo studies, we cultured the enriched thymic progenitors from 
Rag1
-/-
 mice in an in vitro system conducive for precursor development.  Early in vitro 
studies showed that NK1.1
+
 cells can differentiate from ELP when cytokine such as SCF, 
IL7, Flt3L, and IL15 are added to the culture [22].  However, it was later shown that 
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developing ELPs need to come in direct contact with BM stromal cells to acquire a 
phenotype that resembles conventional splenic NK cells, thereby expressing molecules 
such as Ly49 receptors [23-25] .   
 In these studies, we confirmed that OP9 stromal cells and all cytokines were 
necessary for the growth of NK1.1
+
 wells, resulting in a low to negative yield of NK1.1
+
 
cells if any component was excluded during the culture (data not shown).  For the most 
part, we seeded irradiated OP9 cells in 96 well U-bottom plates 24 hours before co-
culture to allow them to settle to the bottom of the well and form a confluent monolayer 
essential for progenitor development.  Microscopic images showed the progenitors made 
direct contact with the OP9 cells for the first 8-9 days of culture, but by day 10, the center 
of the well was devoid of the stromal cells and instead was populated by the developing 
cells (Figures 5,10).  This suggested that OP9 cells were essential for the early stages of 
development, while the cytokines were important for any further maturation during later 
time points. 
 In addition, it was crucial that the OP9 stromal cells were in a healthy condition 
before and during co-culture.  Surprisingly, a simple change in FBS (from Biomeda to 
Sigma) resulted in a morphological change in OP9 cells which affected their ability to 
adhere to the bottom of the well, thereby leading to early cell death.  Without the OP9 
monolayer, the sorted DN1 CD122
-
NK1.1
-
 thymocytes did not receive the proper cell-to-
cell signaling required for differentiation (data not shown).  After replacing the new 
Sigma FBS with Biomeda FBS, we were once again able to detect NK1.1
+
 cells after 7 
days in culture (data not shown and Figure 6B).  This data suggest that direct and 
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constant interaction between healthy stromal cells and DN1 CD122
-
NK1.1
-
 thymocytes is 
necessary for the generation of NK1.1
+
 cells. 
   Besides showing that OP9 cells and cytokines are essential for in vitro NK1.1
+
 
differentiation, our results also showed that the cultured cells did not represent an 
outgrowth of mature NK cells since these do not require OP9 cells to proliferate.  This 
was further confirmed by the absence of any detectable CD122 and NK1.1-expressing 
cells after 4 days in culture.  By assessing marker expression at different time points we 
were also able to follow the gradual acquisition of markers associated with developing 
NK cells, which would not have been possible if there was a contaminating mature NK 
population.   
 Unlike their conventional counterparts in the spleen, little is known about thymic 
NK cells.  While our in vitro differentiated cells resembled thymic NK cells and not 
conventional NK cells, there were some subtle differences.  For example, when we 
analyzed the in vitro generated cells after being in culture for 19 days, we were unable to 
detect DX5 and CD69 expression, markers typical of thymic NK cells.  It was only after 
we optimized the culture by "resting" the cells in LD IL15 alone that the in vitro cells up-
regulated DX5 and CD69, a marker generally associated with cell activation, while 
down-regulating CD11b.  In addition, subtle differences in the expression levels of Ly49 
molecules in thymic and in vitro generated NK cells may be due to stromal factors that 
regulate Ly49 expression that are difficult to recapitulate in vitro [24].  For example, 
irradiation may alter stromal molecules or the MHC on OP9 cells could affect Ly49 
expression or acquisition.  These in vitro studies perhaps reflect a dynamically changing 
in vivo cytokine environment during normal development.  Regardless, the studies 
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described here provide future opportunities to dissect the influence of differing cytokine 
environments and stromal components on thymic NK cells and their development. 
 Moreover, functional studies showed that unlike their splenic counterpart, thymic 
and in vitro generated NK cells are less efficient at degranulating upon target cell 
encounter, yet more efficient at secreting certain cytokines such as TNF.  Although the 
exact function of this NK cell subset has yet to be elucidated, we can speculate that it 
may produce a specific cytokine or chemokine upon activation which has not been 
identified.  The recent discovery of the NK-22 subset in mucosal tissues which can 
secrete IL22, IL26 and leukemia inhibitor factor upon IL23 exposure, suggests that 
different NK cell subsets may have differing roles [58].  While the function of these cells 
may include protecting mucosal sites by constraining inflammation during bacterial 
infection, the specific role of CD127
+
 thymic NK cells is not yet clear.  Future studies 
looking at the effect of depleting these cells in vivo will help us further examine their 
function within the thymus and other tissues. 
 While our studies demonstrate that thymic-like NK cells can differentiate from 
DN1 CD122
-
NK1.1
-
 cells, more work is needed to determine if a single progenitor cell in 
the thymus could give rise to this particular CD127
+
 NK cell subset.  In addition, it has 
yet to be determined whether these progenitors are pre-committed to this specific NK 
lineage once they home to the thymus or if experimental constraints allowed preferential 
development of thymic NK cells.  Future studies where the DN1 population is further 
dissected will help us answer some of these questions. 
 To our knowledge, our studies were the first to attempt to determine the 
progenitor frequency in which a thymic precursor can give rise to an NK1.1-expressing 
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population by limiting dilution analysis.  Since the putative DN1 CD122
-
NK1.1
-
 
progenitor population that differentiates into thymic NK cells has yet to be determined, 
we lack the point of reference to compare our findings.  While one out of every 416  DN1 
CD122
-
NK1.1
-
  thymocytes may seem like a low frequency, it should be noted that this 
precursor population is negatively defined by lack of marker expression (CD4, CD8, 
CD117, CD122, NK1.1), rather than the expression of markers associated with high 
progenitor frequency.  Nonetheless, it should also be emphasized that we enriched for a 
thymic NK cell precursor by using Rag1
-/-
 thymi and sorted for the DN1 CD122
-
NK1.1
-
  
population which represents approximately 0.0073% of C57BL/6 (WT) thymocytes (data 
not shown).  Future experiments to enrich for the putative DN1 CD122
-
NK1.1
-
 
progenitor, perhaps the CD117
+
 population mentioned in Chapter 3, may be informative 
to markedly increase precursor frequency to about 1/10.  Nonetheless, these studies show 
that this in vitro approach is feasible for the differentiation of thymic progenitors to 
CD127
+
NK1.1
+
 cells that phenotypically and functionally resemble thymic NK cells. 
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Figure 5.  Differentiating thymic precursors can be visualized by day 10. Sorted DN1 
CD122
-
NK1.1
-
 thymocytes from Rag1
-/-
 mice were co-cultured with OP9 cells and IL7, 
Flt3L, SCF, and IL15.  Wells were visually and microscopically examined for growth on 
different days. Top panels are at 4X magnification, while bottom panels are at 20X 
magnification.  Data are representative of more than three experiments 
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Figure 6.  Thymic progenitors can differentiate into NK 1.1
+
 cells in vitro. Sorted 
DN1 CD122
-
NK1.1
-
 thymocytes from Rag1
-/-
 mice were co-cultured with OP9 cells and 
cytokines.  A) Growth positive wells by visual inspection were pooled, stained, and 
analyzed for expression of NK1.1 after 19 days in culture.  For the negative controls, 
cells were either left unstained (gray-filled histograms) or stained using the appropriate 
isotype antibody (black dotted histogram).  Cells were gated based on lymphocyte 
population by scatter parameters.    B) Kinetic analysis of NK1.1 and CD122 expression 
on lymphocyte population, gated by scatter parameters.  At varying culture periods, wells 
were examined for the indicated markers as described in Figure 6A.  Data are 
representative of at least three experiments. 
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Figure 7.  All visually growth positive wells were NK1.1
+
.  Sorted DN1 CD122
-
 
NK1.1
-
 thymocytes from Rag1
-/-
 mice were co-cultured with OP9 cells and cytokines at 
limiting cell densities for 19 days. Growth-positive wells were analyzed for NK1.1 
expression by flow cytometry.  Cells were gated on the lymphocyte population.  (A) 
Histograms from one representative well for each seeding dose are shown.  (B) 
Histograms show all growth-positive wells for progenitors seeded at 300 cells/well.  Data 
represent three experiments. 
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Table I and Figure 8.  Limiting dilution analysis (LDA) of DN1 CD122
-
 NK1.1
-
 
thymocytes to determine progenitor frequency.  Sorted DN1 CD122
-
 NK1.1
-
 
thymocytes from Rag1
-/-
 mice were co-cultured with OP9 cells and cytokines at limiting 
cell densities for 19 days. Growth-positive wells were analyzed for NK1.1 expression by 
flow cytometry.  The frequency of growing cells was determined using Poisson 
distribution :  Y=(e-m)(mr)/r!, where Y is the expected fraction of wells with r precursors 
when there is a mean of m precursors per well.  Growth-negative wells are plotted as a 
function of the number of sorted thymocytes added per well using the Graphpad Prism 
software.  The frequency is 0.24%. Standard error is 0.027% and 95% confidence interval 
is 0.3% to 0.17%.  Data represent three experiments. 
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Figure 9.  Phenotypic profile of cells generated in vitro from thymic progenitors.  
Cells cultured in vitro were pooled on different days and assessed for marker expression 
via flow cytometry.  Black histograms represent cells stained with appropriate isotype 
controls and colored-line histograms correspond to different days of analysis.  Early (A) 
and late (B) marker acquisition is shown.  Expression on gated NK1.1
+
 cells is shown, 
except for all markers on day 4 and NK1.1 expression on different days, which were 
gated on the lymphocyte population.  Data are representative of 3-5 experiments.  
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Figure 10.  Developmental kinetic profile of NK1.1
+
 cells generated in vitro from 
thymic progenitors.  Sorted DN1 CD122
-
 NK1.1
-
 thymocytes from Rag1
-/-
 mice were 
co-cultured with OP9 cells and cytokines at limiting cell densities for 19 days.  Cells 
were pooled on different days and assessed for marker expression via flow cytometry.  
Developmental kinetics of sorted thymocytes as a function of days versus the percentage 
of NK1.1
+
 cells expressing the given marker.  Data are representative of 3-5 experiments. 
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Figure 11.  In vitro developed NK1.1
+
 cells resemble those found in the thymus and 
not   conventional splenic NK cells.  Cells from indicated tissues of Rag1
-/-
 mice, along 
with in vitro differentiated NK cells were analyzed by cytometry.  Gray-filled histograms 
represent cells stained with an isotype control and blue-line histograms represent cells 
stained with the indicated antibody.  In vitro generated NK cells were compared to 
freshly isolated splenic and thymic NK cells.  Gated NK1.1
+
 cells are shown.   Data are 
representative of 5 experiments.  
63 
 
 
 
 
 
 
 
 
 
 
 
 
CD25
100 101 102 103 10
0
20
40
60
80
100
12.4
4
100 101 102 103 104
0
20
40
60
80
100
71.6
99
100 101 102 103 104
0
20
40
60
80
100
CD62L
100 101 102 103 104
86
100 101 102 103 104
42.6
100 101 102 103 104
18.9
CD11b
0
20
40
60
80
100
100 101 102 103 104
96.5
100 101 102 103 104
0
20
40
60
80
100
40.3
100 101 102 103 104
0
20
40
60
80
100
32
DX5Pan-Ly49 CD69CD127
100 101 102 103 104
0
20
40
60
80
100
13.8
100 101 102 103 104
0
20
40
60
80
100
96.9Spleen
Thymus
100 101 102 103 104
0
20
40
60
80
100
56.9
100 101 102 103 104
0
20
40
60
80
100
79.1
100 101 102 103 104
0
20
40
60
80
100
40.8
100 101 102 103 104
0
20
40
60
80
100
83.2
100 101 102 103 104
0
20
40
60
80
100
91.3
100 101 102 103 104
0
20
40
60
80
100
55
100 101 102 103 104
0
20
40
60
80
100
41.7
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
In vitro 
Day 19
%
 o
f 
m
a
x
100 101 102 103 104
0
20
40
60
80
100
84.7
 
 
 
 
64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.  Ly49 receptors expressed in splenic, thymic and in vitro derived NK 
cells.  Cells from indicated tissues of Rag1
-/-
 mice, along with in vitro differentiated NK 
cells were analyzed by cytometry.  Gray-filled histograms represent cells stained with an 
isotype control and blue-line histograms represent cells stained with the indicated Ly49 
antibody.  In vitro generated NK cells were compared to freshly isolated splenic and 
thymic NK cells.  Gated NK1.1
+
 cells are shown.   Data are representative of 4 
experiments. 
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Figure 13.  In vitro generated NK1.1
+
 cells closely resemble thymic NK cells after a 
change in culture condition.  The phenotype of in vitro generated NK cells in culture for 
19 days (top panel) was compared to that of cells that were removed from culture after 19 
days and rested in LD IL15 for 36 hrs (bottom panel).  Gated NK1.1
+
 cells are shown.  
Data are representative of 2 experiments. 
 
67 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 101 102 103 104
0
20
40
60
80
100
77.9
100 101 102 103 104
0
20
40
60
80
100
81.6
100 101 102 103 104
0
20
40
60
80
100
87.7
100 101 102 103 104
0
20
40
60
80
100
32
100 101 102 103 104
0
20
40
60
80
100
CD11b
%
 o
f 
m
a
x
100 101 102 103 104
0
20
40
60
80
100
41.7
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
88.1
100 101 102 103 104
0
20
40
60
80
100
53
100 101 102 103 104
0
20
40
60
80
100
71.6
CD127CD25Ly49 DX5
100 101 102 103 104
0
20
40
60
80
100
96.6
CD69
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
36 
hrs
0 
hrs
 
 
 
68 
 
 
 
 
 
 
 
Figure 14.  In vitro generated NK1.1
+
 cells are in an activated state.  Cytokine 
production from in vitro differentiated NK cells grown in culture for 19 days was 
compared to that produced by freshly isolated Rag1
-/-
 splenic and thymic NK cells.  
Sorted NK1.1
+
 cells were stimulated with IL12+IL18 or plate-bound anti-NK1.1 for 8 
hours.  Supernatants were collected and cytokines secreted were assessed by cytometric 
bead array (CBA).  All experimental conditions were done in triplicates.  Data are 
representative of 3 experiments  
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Figure 15.  In vitro generated NK1.1
+
 cells reach a "resting" state after culturing in 
LD IL15 alone.  Sorted DN1 CD122
-
 NK1.1
-
 thymocytes from Rag1
-/-
 mice were co-
cultured with OP9 cells and cytokines for 19 days.  Cells were then pooled, washed with 
PBS and seeded in LD IL15.  Every 12 hours, we collected cells and cultured them in 
either R10 or R10 supplemented with IL12+IL18 for an additional 8 hours.  Supernatants 
were collected and cytokine secretion was assessed by CBA.  Data are representative of 2 
experiments. 
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Figure 16.  In vitro generated NK1.1
+
 cells are functional.  The function of in vitro 
differentiated NK cells grown in culture for 19 days then rested in LD IL15 was 
compared to the function of Rag1
-/-
 splenic and thymic NK cells cultured in LD IL15.  
Sorted NK1.1
+
 cells were stimulated with IL12+IL18 or plate-bound anti-NK1.1 for 1hr, 
Brefeldin A was added and cells were further incubated for 7 hours.   IFN production 
was measured by intracellular flow cytometry.  For negative controls, cells were either 
not stained (gray-filled histograms) or not stimulated (black-dotted histograms).  All 
histograms are gated on NK1.1
+
 cells.  Data are representative of 2 experiments. 
73 
 
100 101 102 103 104
0
20
40
60
80
100
85.2
100 101 102 103 104
0
20
40
60
80
100
26.3
100 101 102 103 104
0
20
40
60
80
100
83.8
100 101 102 103 104
0
20
40
60
80
100
12.4
100 101 102 103 104
0
20
40
60
80
100
29.6
100 101 102 103 104
0
20
40
60
80
100
77.2
IL12/18 PK136
%
 o
f 
m
a
x
IFN
Spleen
Thymus
Cultured
 
74 
 
 
 
 
 
 
 
 
 
Figure 17.  In vitro generated NK1.1
+
 cells secrete cytokines when activated.  The 
function of in vitro differentiated NK cells grown in culture for 19 days then rested in LD 
IL15 was compared to the function of Rag1
-/-
 splenic and thymic NK cells cultured in LD 
IL15.  Sorted NK1.1
+
 cells were stimulated with IL12+IL18 or plate-bound anti-NK1.1 
for 8 hours.   Cytokines secreted were assessed by cytometric bead array.  All 
experimental conditions were done in triplicates.  Data are representative of 2 
experiments. 
75 
 
 
 
 
 
 
76 
 
 
 
 
 
 
 
 Figure 18.  In vitro generated NK cells resemble the function of thymic NK cells.  
The function of in vitro differentiated NK cells grown in culture for 19 days then rested 
in LD IL15 was compared to the function of Rag1
-/-
 splenic and thymic NK cells cultured 
in LD IL15.  Sorted NK1.1
+
 cells were co-cultured with YAC-1 target cells for 2 hours.  
CD107 degranulation upon target encounter was measured by flow cytometry.  All 
experimental conditions were done in triplicates.  Data are representative of 2 
experiments. 
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CHAPTER 5 
GENE PROFILES AND THE IDENTIFICATION OF  
OTHER NOVEL RECEPTORS 
 
79 
 
 Our in vivo and in vitro studies indicate that DN1 CD122
-
NK1.1
-
 thymocytes 
harbor a putative population which can differentiate into NK1.1
+
 cells.  These cells 
phenotypically resemble thymic NK cells.  Thus far, most of our studies have assessed 
surface molecule expression with the use of flow cytometry.  This approach has allowed 
us to follow the sequential acquisition of many markers.  While both the in vitro 
generated and thymic NK cells were shown to be NK1.1
+
CD127
+
Ly49
low
CD11b
low
, a 
more detailed analysis must be done to further understand what makes these cells unique.  
Herein, we attempt to further compare in vitro generated NK cells, thymic NK cells, and 
splenic NK cells by gene expression profiling.          
 
Gene expression profiling of splenic, thymic, and in vitro generated NK cells 
 To further examine the characteristics that make the in vitro generated and thymic 
NK cells distinct, we compared their gene expression to that of their splenic counterpart.  
Briefly, DN1 CD122
-
NK1.1
- 
thymocytes were cultured with OP9 stromal cells and 
cytokines for 19 days.  At this time, all wells were pooled, stained, and sorted based on 
NK1.1
+
 expression.  While essentially all cells expressed NK1.1, it was essential we 
excluded any cells that could potentially alter our results.  In parallel experiments, we 
harvested spleen and thymus from Rag1
-/-
 mice, made single cell suspensions and 
enriched for the NK1.1
+ 
cells via cell sorting.  Total RNA was isolated and gene 
expression profiling was performed using genome-wide oligonucleotide microarrays (see 
Methods).  Total RNA from 3 different experiments was pooled for target synthesis and 
three target samples were pooled and hybridized to each chip, resulting in three chips for 
each cell type. 
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 By utilizing the Partek® Genomics Suite™, microarray chips were normalized 
and unsupervised hierarchical clustering of the data grouped all three samples together 
(Figure 19).  PCA (principal component analysis) mapping showing the global analysis 
of the genome, suggested that there was good concordance of the results between 
replicate samples in each group.  This was essential since triplicate gene chips were not 
only going to be compared to each other, but to other triplicate chips from the remaining 
samples. 
 Due to multiple sample comparison, we applied the Bonferroni correction to 
further normalize gene profiles.  Genes with a significant Bonferroni p-value of less than 
0.02 were graphed in a heat map and lists indicating their fold change were created 
(Figure 20 and Table II).  Results showed that in vitro generated NK cells had a 
significant fold increase in granzyme D, granzyme E, and granzyme G expression.  In 
addition, in vitro NK cells had approximately 6 times more lymphotoxin A (LT) and 
tumor necrosis factor ligand.  While surface expression showed that these cells were 
similar, transcript profiles suggest there may be some subtle differences created by the in 
vitro culture conditions. 
 To further examine the difference between splenic and thymic NK cells, we 
mapped genes with a Bonferroni p-value of less than 0.02 (Figure 21 and Table III).  As 
expected, we were able to detect a 4 fold difference in CD127 expression in thymic NK 
cells, where splenic gene expression was down.  Surprisingly, we detected integrin alpha 
E (CD103), IL2 receptor alpha chain (IL2R, CD25), and cadherin 1 at a 25, 40, and 97 
fold increase in thymic NK cells respectively.  However, splenic NK cells had higher 
expression of Fc receptor IgG2b (CD32)  and CD86.  Together, these results not only 
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validate the our functional assays where splenic NK cells were more efficient at 
degranulating, perhaps due to CD32 expression, but also suggest that thymic NK cells are 
even more unique in their phenotype, expressing CD25 and CD103, than conventional 
NK cells. 
 Finally, we compared the gene expression profile of splenic NK cells to that of 
thymic and in vitro NK cells combined (Figure 22 and Table IV) .  By filtering genes out 
with a Bonferroni p-value of 0.01, we were able to detect many of the similar genes 
already described.  Results showed that splenic NK cells had higher KLRG1, CD32, and 
CD86 transcript expression.  However, both thymic and in vitro NK cells expressed more 
CD127, CD25, CD103, LT, and granzymes D and E.  To verify these results, we stained 
for some of the surface receptors and analyzed them via flow cytometry (Figure 23).  
Results confirmed the gene expression profiles, but future intracellular flow and RT-PCR 
experiments will be done to validate other transcripts found to be significant.  These 
results further support our hypothesis that DN1 CD122
-
NK1.1
-
 thymocytes can 
differentiate into NK1.1
+
 cells that very closely resemble thymic NK cells, and not 
conventional splenic NK cells.  
  
Novel marker expression is specific to NK cells differentiated in a thymic 
environment  
 While extracellular CD25 was detected on in vivo, in vitro, and thymic NK cells 
during previous experiments (Figures 4, 9-11, 13, 24), the presence of CD103 transcripts 
in thymic NK cells was an interesting finding.  To determine if the CD103 protein was 
expressed on the cell surface, we once again differentiated DN1 CD122
-
NK1.1
-
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thymocytes into NK1.1
+ 
cells in vivo and in vitro (Figure 24).  Adoptive transfer 
experiments showed about half of Ly5.2
+
NK1.1
+
 (donor-generated) cells found in the 
thymus of IT transferred mice, expressed CD103.  Although the same percent of cells 
also expressed CD25, there was no correlation between the two surface molecules (data 
not shown).  In addition, both CD103 and CD25 detection on thymic Ly5.2
+
NK1.1
+
 cells 
was significantly lower than their control unmanipulated counterparts (Figures 23, 24).  
This may be a direct consequence from irradiating the host mice.  Regardless, these 
results suggest that thymic progenitors can generate CD103
+
 NK cells. 
 To investigate the kinetics of CD103 acquisition, we cultured DN1 CD122
-
NK1.1
-
 thymocytes in vitro with OP9 stromal cells and cytokines.  Once again, 
differentiating cells were harvested at certain time points and their phenotypic profiles 
were assessed via flow cytometry (Figure 10).  Results showed that while less than 10% 
of NK1.1
+
 cells expressed low levels (MFI) of CD103 on day 7, we were able to detect a 
higher MFI on more than 60% NK1.1
+
 cells on day 13 (Figure 10 and data not shown).  
This expression was shown to be stable since NK cells were still CD103
+
 on day 19.  
This suggest that CD103 expression is acquired during the early stages of development, 
more specifically during stage II.  Furthermore, by altering the culture conditions we 
were able to show that essentially all (96%) in vitro generated NK1.1
+
 cells expressed 
CD103 at similar detection levels as thymic NK cells (Figures 23, 24).  Taken together, 
these results once again verify that the in vitro generated NK cells very closely resemble 
thymic NK cells. 
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Expression of CD127
+ 
NK cells in the absence of CD25 and CD103 
 To examine whether CD25 or CD103 influence the generation of thymic NK 
cells, we looked for CD127
+
NK1.1
+
 cells in different strains of mice including B6, 
CD103
-/-
 on a B6 background, Rag1
-/-
, and CD25
-/-
 on a Rag1
-/-
 background.  As 
expected, less than 15% of splenic NK cells in B6 and Rag1
-/-
 mice express CD127, while 
essentially all thymic NK cells are CD127
+
.  Similar results were obtained in CD103
-/-
 
mice.  Surprisingly, we detected CD127 at a lower MFI on less than half of thymic 
NK1.1
+
 cells in CD25
-/-
Rag1
-/- 
mice (Figure 25A).   
 Although the percent of NK cells that expressed CD127 was comparable between 
B6, CD103
-/-
, and Rag1
-/-
 mice, and lower on CD25
-/-
Rag1
-/- 
mice,  their absolute 
numbers varied significantly (Figure 25B).  Compared to WT B6 mice, a larger number 
of CD127
+
 NK cells were detected in the thymus of CD103 KO (knockout) mice, 
approximately 1.5 times more cells.  However, CD127 was detected in only one tenth 
(1/10) of thymic NK cells in Rag1
-/-
 mice, compared to WT.  Furthermore, while a 
smaller percent of thymic NK cells from CD25
-/-
Rag1
-/- 
mice were positive, their absolute 
number was 4 times greater than that in thymic NK cells from Rag1
-/- 
mice.  Together, 
these results suggest that CD103 expression in a WT background, and CD25 in a RAG 
background are not necessary for thymic NK cell development, but may be important for 
the export of these cells. 
 
Thymic NK cells in the periphery 
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 CD103 has been shown to be expressed in T lymphocytes and dendritic cells 
(DCs) that reside in the intestinal mucosa [59, 60].  Since FACS analysis and gene 
expression profiles showed that thymic NK cells also expressed abundant CD103, we 
assessed whether this 
 
NK subset also had the potential to travel to the intestinal mucosa 
(Figure 26).  Results showed that although the percent of NK cells in the small and large 
intestine (SI and LI, respectively) was low, these cells were still detectable.  A population 
of NK1.1
+
 cells in both areas of the intestine were CD127
+
, while only those in the small 
intestine were CD103
+
.  A more in-depth phenotypic analysis of NK1.1
+
 cells found in 
the small intestine showed these cells resembled thymic NK cells in that they expressed 
CD25 and low levels of Ly49 and CD11b (Figure 27).  These preliminary studies may 
indicate that a small population of thymic NK cells have the potential to emigrate from 
the thymus and seed other tissues, perhaps partially guided by the CD103 integrin. 
 
Discussion 
 While phenotype analysis was essential to our kinetics experiments, we further 
characterized both thymic and in vitro generated NK cells by examining their genome-
wide expression profiles and comparing them with that of splenic NK cells.  To ensure 
the RNA isolated from sorted NK1.1
+
 cells represented a whole population and not just 
one mouse, we pooled RNA from 3 independent experiments.  Due to the small amount 
of RNA, the Washington University Gene Core Facility performed two rounds of linear 
amplification, creating a target synthesis for hybridization to Affymetrix 430 v2.0 
GeneChips, which offers complete coverage of over 39,000 transcripts on a single array 
[61].  Three of these target samples were then pooled and hybridized to each chip.     
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 We assessed statistical significance by using the q value of false discover rate 
(qFDR) based on the Bonferroni correction (Bonferroni p-value), which corrects for 
multiple test samples.  In this study, we defined the qFDR< 0.01 or <0.02 to be 
statistically significant.  Although the Bonferroni correction is usually overly stringent for 
microarray data analysis, there will still be a 1-2% chance that a single false positive will 
be present if the p-value cutoff is 0.01 to 0.02.  Regardless, we were able to identify 
several distinct gene transcripts present in either spleen, thymus, or in vitro NK cells.  
 When we compared the gene expression profile of in vitro NK cells to the profile 
of thymic NK cells, we were able to detect significantly higher amounts of  granzymes 
and LT transcripts in the in vitro population.  Whereas most granzymes are structurally 
related serine proteases, they differ in their substrate specificity [5].  In mice, four 
granzyme orthologues can be found, including A, B, K, and M.  While it has been shown 
that the murine genome encodes several other granzymes (D, E, F, G, L, and N), little is 
known about them [62].  Recent studies have shown that granzymes D-G were expressed 
on granulated metrial gland (GMG) cells, which belong to the NK lineage, located in the 
decidua and metrial gland during mid-gestation in mice [63].  In this study, expression of 
the genes for granzymes D-G was found to be developmentally regulated in murine GMG 
cells during pregnancy.  These granzymes were shown to be expressed in late gestation, 
in contrast to the mid-gestational expression of granzyme A.  Furthermore, expression of 
granzymes D-G was shown to be up-regulated by both IL2 and IL15 in in vitro culture 
experiments.  These finding suggests different roles for granzymes D-G compared with 
granzyme A.  
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 The fact that transcripts for granzymes D, E, and G were found in in vitro cells 
but not in thymic NK cells indicates that the culturing conditions influenced their 
expression.  When culturing our cells, we add a high dose of IL15 to push NK lineage 
commitment, proliferation, and survival.  In addition to IL15, studies have shown that 
stromal cells support HSC differentiation via LT engagement [19], which could also 
explain why in vitro NK cells had a higher number of transcripts.  In any case, these 
experiments were carried out prior to discovering that in vitro NK cells are in a pre-
activated state at day 19 of culture.  Further gene expression microarrays will need to be 
done on "rested" in vitro NK cells for a fair comparison to thymic NK cells. 
 When the gene expression profile of splenic NK cells was compared to the thymic 
NK cells, we were able to detect a 40-fold increase in CD25 expression in thymic NK 
cells.  Although gene expression profiles validated our phenotypic results in regards to 
CD25 expression on thymic NK cells, we still do not know the basis for this difference at 
the moment.  The expression of this IL2R on thymic NK cells from Rag1
-/-
 mice, but not 
on WT B6 mice, suggest it might be specific to this strain.  
 Interestingly, we also detected a 26-fold increase in CD103 expression in thymic 
NK cells.  Also termed integrin E7, CD103 was first identified through its selective 
expression on more than 90% of CD8 T cells, approximately 40-50% of CD4
+ 
T 
lymphocytes, and a subset of DCs, all of which are found in the intestinal mucosa [64-
67].  The gastrointestinal tract is exposed to continuous antigenic challenges including 
food antigens, bacterial antigens of the normal bacterial flora and pathogens.  The 
intestinal immune system therefore must be able to defend against these pathogens while 
maintaining tolerance to the normal bacterial flora and food antigens.   
87 
 
 Studies have shown that T cells in intestinal mucosa undergo a shift in expression 
of cell surface adhesion molecules upon stimulation [68].  Also, transforming growth 
factor-1 (TGF-1) has been shown to induce expression of E7 on almost half of the 
peripheral T lymphocytes during in vitro cultures [60].  While CD103 binds to E-
cadherin [69, 70], and possibly to other ligands [71], it has been shown to mediate T cell 
adhesion to epithelial cells [72, 73] .  In addition, this integrin has been shown to transmit 
an outside-in signal that enhances T cell proliferation and induces redirected lysis of FcR-
bearing target cells [59].  Furthermore, there is a decrease in the number of gut IEL's, 
particularly of the TCR + CD8+ subset in CD103-/- mice, suggesting that its expression 
may be involved in either the generation or maintenance of this IEL subset [74]. 
Together, these studies indicate that the expression of CD103 may influence thymic NK 
cells to emigrate from the thymus and seed mucosal tissues, such as the gut.  Here, these 
cells may have the potential to carry out a specific function that may differ from the 
effector function seen in their splenic counterparts. 
 The detection of these two novel receptors (CD25 and CD103) prompted us to 
question whether either molecule affected or influenced the development of thymic 
CD127
+
 NK cells.  Because CD25 was only expressed by thymic NK cells in Rag1
-/-
 
mice, we backcrossed these two strains.  Although a smaller percent of thymic NK cells 
were shown to express CD127 in this strain, their absolute number was 4 times greater 
than in Rag1
-/-
 mice.  In a similar situation, CD103
-/-
 mice had an higher absolute number 
of CD127
+
 NK cells in the thymus compared to WT B6 mice.  This suggests that while 
CD25 or CD103 may not have an effect on thymic NK cell development, it may 
influence the export of these cells from the thymus.       
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 Although our knowledge of thymic NK cell development, receptor repertoire,  
and function is still in its infancy, we have shown that these cells express novel receptors 
that may give us clues as to their specific effector function.  Herein, we have shown that 
our method of gene expression profiling is a feasible and reliable method to characterize 
splenic, thymic, and in vitro NK cells in a more in-depth manner.  Along with phenotypic 
and functional analysis, gene expression profiles further confirmed that the in vitro 
generated NK cells closely resemble thymic NK cells, both of which are distinct from 
their splenic counterpart.  
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Figure 19.  PCA map of splenic, thymic, and in vitro generated NK cells.  NK1.1
+
 
cells from spleen and thymus of Rag1
-/-
 mice, along with in vitro differentiated NK cells 
were sorted, RNA was isolated and gene expression was assessed by genome-wide 
microarrays.  PCA mapping is a global analysis of the genome and not of any gene in 
particular.  Samples that are close together are similar across the whole genome.  Each 
chip represents 3 pooled samples independently sorted from 10-20 mice. 
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Figure 20.  Gene expression profiles of thymic and in vitro generated NK cells.  
NK1.1
+
 cells were generated by using the in vitro system described above.   After 19 days 
in culture, all growth positive wells were pooled and, along with thymic NK1.1
+
 cells 
from Rag1
-/-
 mice, were sorted using Dako MoFlo.  RNA was isolated using the Qiagen 
RNeasy Micro Kit, quantified and submitted to the Multiplex Gene Analysis Core to be 
used in an  Affymetrix GeneChip® microarray.  Transcript expression was analyzed via 
Partek
® Genomic Suite™ and adjusted with a Bonferroni p-value of less than 0.02.  Each 
cell type was done in triplicate.  Data are representative of three gene chips.    
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Table II.  List of gene expression profiles of thymic and in vitro generated NK cells.  
Microarray data from freshly isolated thymic NK cells and in vitro differentiated NK 
cells (day 19) were analyzed with Partek
® Genomic Suite™.  Genes were filtered by 
adjusting the Bonferroni p-value to less than 0.02.  Each cell type was done in triplicate.  
Data are representative of three gene chips.  
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Figure 21.  Gene expression profiles of splenic and thymic NK cells.  NK1.1
+
 cells 
from spleen and thymus in Rag1
-/- 
mice were enriched by FACS sorting.  RNA was 
isolated using the Qiagen RNeasy Micro Kit, quantified and submitted to the Multiplex 
Gene Analysis Core to be used in an  Affymetrix GeneChip® microarray.  Transcript 
expression was analyzed via Partek
® 
Genomic Suite™ and adjusted with a Bonferroni p-
value less than 0.02.  Each cell type was done in triplicate.  Data are representative of 
three gene chips.    
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Splenic
+
1 2 3 1 2 3
Thymic
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Table III.  List of gene expression profiles of splenic and thymic NK cells.  
Microarray data from freshly isolated splenic and thymic NK cells was analyzed with 
Partek
® Genomic Suite™.  Genes were filtered by adjusting the Bonferroni p-value to 
less than 0.02.  Each cell type was done in triplicate.  Data are representative of three 
gene chips. 
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Figure 22.  Gene expression profiles of splenic vs. thymic and in vitro NK cells.  
Along with in vitro generated cells, NK1.1
+
 cells from spleen and thymus in Rag1
-/- 
mice 
were enriched by FACS sorting.  RNA was isolated using the Qiagen RNeasy Micro Kit, 
quantified and submitted to the Multiplex Gene Analysis Core to be used in an  
Affymetrix GeneChip® microarray.  Transcript expression was analyzed via Partek
® 
Genomic Suite™ and adjusted with a Bonferroni p-value of less than 0.01.  Each cell 
type was done in triplicate.  Data are representative of three gene chips.    
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+
Splenic Thymic
1 2 3 1 2 3 1 2 3
In vitro
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Table IV.  List of gene expression profiles of splenic vs. thymic and in vitro NK cells.  
Microarray data from freshly isolated splenic and thymic NK cells, along with in vitro 
generated NK1.1
+ 
cell, was analyzed with Partek
® Genomic Suite™.  Genes were filtered 
by adjusting the Bonferroni p-value to less than 0.01.  Each cell type was done in 
triplicate.  Data are representative of three gene chips 
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Figure 23.  Extracellular staining verifies gene chip results.  Cells from indicated 
tissues of Rag1
-/-
 mice, along with cells differentiated in vitro (day 19) were stained with 
a panel of antibodies and analyzed by flow cytometry.  Gray-filled histograms represent 
cells stained with an isotype control and blue-line histograms represent cells stained with 
the indicated antibody.  In vitro generated NK cells were compared to freshly isolated 
splenic and thymic NK cells.  Gated NK1.1
+
 cells are shown.  N.D. signifies no data 
available.   Data are representative of 3 experiments. 
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Figure 24.  DN1 CD122
-
NK1.1
-
 thymocytes generate CD103
+ 
NK cells in a thymic 
microenvironment.  DN1 CD122
-
NK1.1
- 
 thymocytes from Rag1
-/-
 Ly5.2 mice were 
transferred into irradiated Rag1
-/-
 Ly5.1 mice intrathymically (IT).  32 days post transfer, 
cells were harvested from the spleen and thymus from host mice.  In addition DN1 
CD122
-
NK1.1
- 
 thymocytes were cultured in vitro for 19 days and rested in IL15 alone 
for 36 hours.  All cells were stained and analyzed via flow cytometry.  Gray-filled 
histograms represent cells stained with an isotype control and blue-line histograms 
represent cells stained with the indicated antibody.  Gated NK1.1
+
 cells are shown.   Data 
are representative of 2 experiments. 
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Figure 25.  CD127
+ 
NK cells are present in CD25- and CD103- deficient mice.  Cells 
from indicated tissues of B6, CD103
-/-
,  Rag1
-/-
,  and CD25
-/-
Rag1
-/-
 mice  were harvested 
and assessed for CD127
+
 NK cells by flow cytometry.  Gray-filled histograms represent 
cells stained with an isotype control and blue-line histograms represent cells stained with 
the indicated antibody.  The absolute value was calculated using the parameters specified 
in Flowjo.  Gated NK1.1
+
 cells are shown.   Data are representative of 2 experiments.  
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Figure 26.  CD127
+
 NK cells are present in the intestinal mucosa.  Cells from the 
small and large intestine of Rag1
-/-
 mice were analyzed by flow cytometry.  Gray-filled 
histograms represent cells stained with an isotype control and blue-line histograms 
represent cells stained with the indicated antibody.  Gated NK1.1
+
 cells are shown.  Data 
are representative of 2 experiments.  
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Figure 27.  CD127
+
 NK cells in the small intestine resemble thymic NK cells.  Cells 
from the small intestine of Rag1
-/-
 mice were stained with a panel of antibodies and 
analyzed by flow cytometry.  Gray-filled histograms represent cells stained with an 
isotype control and blue-line histograms represent cells stained with the indicated 
antibody.  Gated NK1.1
+
 cells are shown.   Data are representative of 2 experiments.  
representative of 5 experiments. 
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CHAPTER 6 
DISCUSSION 
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 Our studies showed that highly purified DN1 CD122
-
NK1.1
-
 thymocytes from 
Rag1
-/- 
mice can differentiate into NK1.1
+
 cells.  The emerging NK population is unlikely 
due to contaminating mature NK cells that grew out in the subsequent in vitro cultures for 
a number of reasons:  1) The purified DN1 CD122
-
NK1.1
-
 population from Rag1
-/-
Ly5.2 
mice can give rise to cells with NK cell markers when adoptively transferred into sub-
lethally irradiated Rag1
-/-
Ly5.1 congenic recipients in vivo.  2) Although NK1.1 and 
CD122 are among the earliest markers on developing NK cells, they were not expressed 
at the earliest time points during our kinetic analysis, indicating that the cells acquired 
these markers during differentiation.  3) Kinetic analysis showed the gradual and 
sequential acquisition of markers associated with developing NK cell subsets.  If these 
cultured cells represented outgrowth of mature NK cells, we would have expected that 
they expressed mature markers characteristic of later developmental stages early in the 
culture period.  4) Acquisition of the NK cell markers did not occur unless the cultures 
had all cytokines and OP9 cells, whereas mature NK cells can proliferate with IL15 
alone.  5) Finally, the number of cells expressing the various NK cell markers cannot be 
accounted for by proliferation of a small contaminating pool of mature NK cells which 
typically have a 24 hour doubling time in vitro.  For example, on day 4 we failed to 
detected NK1.1
+
 cells, while on day 7, 35% of the cells were NK1.1
+
.   Taken together, 
these considerations strongly support that DN1 CD122
-
NK1.1
-
 thymocytes can 
differentiate into cells with NK markers in vivo and in vitro. 
 Unlike their conventional counterparts in the spleen, little is known about thymic 
NK cells.  While the vast majority of splenic NK cells originate and develop in the BM, 
early studies have shown the existence of a T/NK bipotential progenitor in the thymus 
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[27-29].  Recent studies showed a similar T/NK bipotential progenitor may be present in 
the BM, based on in vitro differentiation but thymic NK cells did not develop upon 
adoptive transfer, unlike our results [75].  This suggest that these BM precursors lack the 
signals to develop into thymic NK cells.  On the other hand, T/NK bipotential precursors 
are most commonly found within the fetal thymus, thus the possibility of thymic NK cells 
developing within the thymus of an adult mouse has been suggested [27].  Furthermore, 
previous studies did not characterize the NK1.1
+
 cells that developed in vitro in the 
absence of Notch signaling, and thymic NK cells were described subsequently; their 
relationship to thymic NK cells was not investigated.  
  Here, our adoptive transfer studies strongly suggest that bipotential progenitors 
exist in the adult thymus which can differentiate into thymic NK cells rather than 
conventional NK cells.  Taking into account that NK cells do not require gene 
rearrangement for their receptors, unlike T and B cell receptors, we opted to perform all 
of our experiments using Rag1
-/-
 mice on a C57BL/6 background.  This approach was 
supported by a recent publication indicating that thymic NK cells are not derived from 
thymocytes having undergone antigen receptor rearrangement [43].  Pre-sort analysis 
showed that only a very small percent of thymocytes were in the DN1 
(CD44
+
CD25
low/neg
) stage of development, while most cells were arrested in the 
DN2/DN3 stage due to the lack of RAG genes.  After sorting DN1 CD122
-
NK1.1
-
 
thymocytes, we injected them intrathymically into Rag1
-/-
Ly5.1 congenic recipients.  
Host mice had to be sub-lethally irradiated since we were unable to detect any Ly5.2
+
 NK 
cells during our pilot studies with transfer into unmanipulated mice.  Our in vivo studies 
also showed that thymic cells transferred intravenously failed to develop.  This may be a 
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direct consequence of the inability of these cells to develop in other tissues, such as the 
spleen, or the failure to home back to the thymus for development, or both.  Regardless, 
when the DN1 population was directly injected into the thymus of host mice, we not only 
detected donor NK1.1
+
 cells in the thymus, but also in the spleen.  The presence of donor 
NK cells in the spleen may suggest that they develop in the thymus and have the potential 
to migrate and seed other sites.  A second, though not mutually exclusive, explanation is 
that at some stage during development, a small percent of cells may escape the thymic 
environment, seed the spleen, and finish their maturation.  Although further studies will 
be required to distinguish among these possibilities, our current studies indicate that the 
adult murine thymic DN1 population harbors progenitors that develop within the thymic 
environment into NK1.1
+
 cells that resemble thymic NK cells. 
 While the differentiated cells from our adoptive transfer experiments were too 
few for detailed analysis, we were able to study the in vitro differentiated cells in greater 
detail.  Early studies examining the heterogeneity of the thymic DN1 population showed 
that T cells or NK cells could be generated in vitro using either OP9 cells with or without 
the expression of the Notch ligand Delta-like 1 (OP9-DL1), respectively.  These studies 
showed that after six days of DN1/OP9 co-culture, NK1.1-expressing cells could be 
detected [33].  A recent study indicates that BM-derived precursors can also differentiate 
into NK1.1
+
 cells with a similar in vitro system [75].  However, in either case, the NK 
cells generated from this progenitor population were not further characterized.   
 In a similar manner, we seeded our sorted DN1 population on irradiated OP9 cells 
and added Flt3L, SCF, IL15, and IL7 to create an environment conducive for NK 
differentiation.  By pooling wells on different days, we were able to delineate the kinetics 
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of developmental markers.  Within 7 days, our sorted population had differentiated into 
CD122
+
NK1.1
+
 cells.  The acquisition of other markers seem to be following the stages 
proposed by Kim and colleagues, where CD94, NKG2D, Ly49, CD43 and CD11b are 
sequentially up-regulated following CD122 and NK1.1 expression [20].  However, low 
Ly49 and CD11b MFI, together with the early CD25 and late CD127 expression, made 
the in vitro differentiated NK1.1
+
 cells distinct from conventional BM NK differentiation.  
Regardless of the percent of cells that expressed each marker, we were able to detect the 
acquisition and the uniform increment of expression, as compared to isotype controls, of 
the positive population as time progressed.  These studies suggest that conventional 
splenic and thymic NK cells undergo similar initial stages during development.  
 For the most part, the DN1 CD122
-
NK1.1
-
 cells were cultured with OP9 cells and 
cytokines for approximately 21-30 days, although the OP9 cells were no longer necessary 
after 13 days.  From day 19 to 25, there was no phenotypic change in the in vitro 
differentiated NK1.1
+ 
cells.  Cell numbers quickly declined if cells were left in culture 
conditions for more than 25 days, thus most experiments were done on day 19.  Our 
studies show that these in vitro  differentiated cells have a phenotype that resemble 
thymic NK cells, thus differing from conventional splenic NK cells.  This was further 
validated when we modified the in vitro culture conditions and incubated the cells in 
IL15 alone which allowed up-regulation of DX5 and CD69, as well as CD127 itself to 
levels remarkably similar to thymic NK cells.  Thus, the DN1 cells differentiated in vitro 
into NK1.1
+
 cells more closely resembling thymic NK cells. 
 Moreover, our studies yielded an unexpected difference with respect to CD25 that 
we and others did not find expressed on wild type thymic NK cells [39, 55].  The basis 
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for this difference is not clear at the moment but at minimum, it appears to be another 
marker selectively expressed on thymic NK cells.  Interestingly, gene chip profiles 
verified that CD25 mRNA was 40- and 20- fold higher in thymic and in vitro NK cells, 
respectively, than in their splenic counterparts.   
 In addition to CD25, microarray profiling also showed CD103 mRNA was 
expressed 26-fold higher on thymic 
 
NK cells.  Thus far, CD103 has been shown to be 
expressed on CD8
+
 and CD4
+ 
T cells in the intestinal mucosa [64-66].  It is also 
expressed on lymphocytes in the genitourinary tract and lungs [76-79].  To our 
knowledge, it has never been shown to be expressed on any NK subset.  The expression 
of this integrin on thymic NK cells may perhaps indicate that these cells differentiate in 
the thymus but ultimately emigrate to mucosal tissues, such as gut or lungs.  While 
functional results showed that both thymic and in vitro generated NK cells have the 
capacity to produce cytokines and displayed degranulation when exposed to NK sensitive 
targets, a more specific role in other tissues is not out of the question.  Further studies 
which will determine if this unique NK subset is present in mucosal tissues will allow us 
to determine if these cells have a different effector function than splenic NK cells, such as 
a tolerogenic role. 
 Although CD127 is thought to be a good marker to identify thymic NK cells, it 
has been shown to be expressed transiently in other lymphocytes [80].  IL7R down-
regulation, which is induced by IL7 signaling, has been proposed to serve as a 
mechanism for T cells to receive pro-survival signals [81].  Cells signaled by IL7 
transiently down-regulate surface expression of IL7R and thus become unresponsive to 
the continued presence of IL7.  This behavior explains how activated T cells undergo 
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rapid expansion, increasing their numbers to almost half of the total number of T cells 
during some acute infections [82].  Upon activation, T cells respond to other cytokines 
such as IL2 and down-regulate IL7Rα and IL7 consumption, presumably in order to 
preserve the naïve repertoire that is critically dependent on IL7.  A similar phenomenon 
is believed to exist between DN and double positive (DP) thymocytes where the DN 
population of lymphocyte precursors is critically dependent on IL7 to give rise to double 
positive (DP) thymocytes [83], or in this case thymic NK cells.  The transient expression 
of CD127 suggest that it is a non-reliable marker for identifying NK cells generated in 
the thymus in other tissues of the periphery.  However, our studies show that CD103 is 
exclusively expressed in thymic NK cells and in vitro differentiated NK cells.  While we 
were able to detect CD103 by day 7, the majority of in vitro NK cells expressed it by day 
13.  This expression was stable in that we were able to detect it consistently at later time 
points.  Furthermore, our studies showed that  all CD127
+
 NK cells were CD103-positive, 
yet not all CD103
+
 NK cells expressed CD127 (data not shown).  With the transient 
expression of CD127 and the constant expression of CD103, we propose that the latter is 
a better identification marker for thymic NK cells.      
 Taken together, our results suggest that DN1 CD122
-
NK1.1
-
 thymocytes harbor a 
population that utilizes the thymic stroma to differentiate into NK1.1 expressing cells.  
Both adoptive transfer and in vitro experiments showed that these cells have a unique 
phenotype including the expression of CD127, CD25, and CD103.  While these cells 
were capable of lysing target cells, they were more efficient at secreting cytokines such 
as TNF.  Nonetheless, the studies described here provide future opportunities to dissect 
the function of thymic NK cells and their development.
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CHAPTER 7 
FUTURE DIRECTIONS 
124 
 
 By utilizing the methods described here, our understanding of NK cell 
development and differences between NK cell subsets has grown expansively.  The idea 
that T/NKPs in the thymus of adult mice could develop into a unique NK cell was 
confirmed with adoptive transfer experiments.  Although our return yield was slightly 
lower than expected, in vitro studies allowed us to further study the DN1 population and 
their association with thymic NK cells.  However, many questions remain regarding 
thymic NK cell development and function that merit further investigation. 
 
Determine if thymic precursors are committed or influenced to become thymic NK 
cells 
  Our studies showed that a small population of DN1 thymic progenitors are 
destined to become thymic NK cells rather than conventional NK cells.  A question that 
remains is whether they acquire this commitment once they reside in the thymus or if 
experimental constraints allowed preferential development of thymic NK cells.  In order 
to address these issues, further dissection of the DN1 progenitor pool will be necessary.   
 First, we must identify the putative progenitor population within the DN1 stage of 
development that leads to the generation of thymic NK1.1
+
 cells. Studies have shown that 
the DN1 thymic population is heterogeneous [84].  To further refine the analysis of DN 
subsets, the expression or absence of CD117 has been included in certain studies [33, 85].  
The level of expression of CD117 by DN thymocytes is very broad and, depending on 
staining strategy, spans two to three logs of fluorescence intensity (data not shown).  
Whereas T lineage cells in the DN1 subset are CD117
bright
, other non-T lineage 
precursors, including those for dendritic cells and NK cells, express intermediate levels of 
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CD117 [84].  We will therefore, attempt to sub-sort the DN1 CD122
-
NK1.1
-
 thymocytes 
according to CD117 expression and culture them in the in vitro conditions described  
above.  A quick phenotypic analysis will indicate which population generates 
CD127
+
NK1.1
+
 cells.  Furthermore, we will re-address progenitor frequency by culturing 
the specific population in limiting numbers.  Current results show that one out of every 
416 DN1 CD122
-
NK1.1
-
 thymocytes generates an NK1.1
+
 population , but it should be 
noted that this precursor population is negatively defined by lack of marker expression 
(CD4, CD8, CD117, CD122, NK1.1), rather than the expression of markers associated 
with high progenitor frequency.   Perhaps by further enriching our starting population, we 
may be able to increase precursor frequency to about 1/10. 
 Once the putative precursor population is identified, we can differentiate them in 
vitro with either our current culture conditions or with different factors that could 
potentially alter the fate of the progenitors.  Currently, we seed the progenitors on OP9 
BM stromal cells and add IL7, SCF, Flt3L, and IL15.  Our attempts to differentiate the 
progenitors in a stroma-free culture, using only cytokines have been unsuccessful (data 
not shown).  For that reason, we will attempt to change the stromal cell line while 
keeping all other factors constant.  Early studies have shown that the AFT024 stromal 
cell line supports murine HSCs by providing a positive stem cell regulator via delta-
like/preadipocyte factor-1 [86].  These cells not only represent the liver micro-
environment, but have also been immortalized with temperature sensitive SV40T antigen, 
which allows them to grow only at 33°C while inhibiting their proliferation at 37°C.  
Results could yield one of three options:  1) The progenitors could give rise to 
CD127
+
NK1.1
+
 cells that resemble thymic NK cells, indicating that these DN1 precursors 
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are precommitted to the thymic NK subset early on.  2) The progenitors could 
differentiate into NK1.1
+ 
cells that do not resemble thymic NK cells, suggesting the 
progenitors are committed to the NK lineage but not the CD127
+
 NK subset.  These 
results could signify that the thymic progenitors are influenced by their environment to 
express a certain receptor repertoire.  3)  Finally, progenitors may not express NK1.1
+
 at 
any time point, indicating the stromal cells are not providing the signals necessary for NK 
development.  Regardless, these results will give us the opportunity to further understand 
the factors involved in NK lineage commitment.  
 While these in vitro results are possible, it will not be feasible to differentiate this 
putative population in vivo.  Our current protocol for adoptive transfer includes 
harvesting the thymus from 80-100 Rag1
-/- 
mice to obtain an appropriate number of DN1 
CD122
-
NK1.1
-
 progenitors.  If this population is further sub-sorted, we will need to 
increase the number of mice used to collect enough of the putative progenitors that will 
generate thymic-like NK1.1
+ 
cells.  For this reason, we will attempt to answer these 
questions in an in vitro system. 
 
Examine transcripts that correlate with the developmental stages of NK cells 
 In addition to surface marker acquisition, it will be important to assess specific 
transcription factors (TF) involved in the differentiation process.  Because the in vitro 
generated NK cells were shown closely resemble thymic NK cells, we can follow the 
expression of TF as they develop.  Thus far, we have initiated these studies by culturing 
the DN1 CD122
-
NK1.1
-
 progenitors in vitro for 4, 8, and 13 days.  We enriched NK1.1
+
 
cells on days 8 and 13 by doing a high-purity sort with MoFlow, while all differentiating 
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cells were collected on day 4.  Total RNA was isolated and target synthesis for 
hybridization to Affymetrix 430 v2.0 GeneChips was performed with two rounds of 
linear amplification.  Total RNA from 3 different experiments was pooled for target 
synthesis and three target samples were pooled and hybridized to each chip, resulting in 
three chips for each cell type.  Although we have received the gene profiles, we have not 
performed detailed analysis of the transcription factors.  
 Since our studies suggest that these cells follow a similar differentiation process 
as BM derived NK cells, we expect to see expression of the most common NKP TFs 
during the early stages of development, such as PU.1, Ets-1, Ikaros, and Id2.  PU.1 has 
been implicated in early NK cell development since deficiency in this transcription factor 
affects expression of the CD127 and the Flt3 receptor [87-89].  Compared to WT, PU.1
-/-
 
fetal liver HSC generated reduced numbers of NKPs when transferred into alymphoid 
Rag2
-/- 
x c
-/-
 mice [90].  Similarly, deficiency in Ets-1 results in the absence of NK cells 
in the bone marrow, spleen, and LN, suggesting NKPs are also reduced or absent [91].  
Furthermore, mice that are deficient in the zinc-finger transcription factor Ikaros display 
severe defects in the development of all lymphoid cell lineages including NK cells, which 
may be due to the diminished expression of Flt3, CD122, and CD117 [92-94].  Finally, 
the inhibitors of DNA binding (Id2) have been shown to heterodimerize with E-box 
transcription factors, thereby titrating them out and inhibiting their transcriptional 
activity.  Since E-box transcription factors are critical mediators of T and B 
lymphopoiesis, their inhibition by Id2 generates NK cell lineage committed NKPs [95, 
96].  Together these transcription factors have been shown to affect NKPs.   
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 During later stages of development, such as day 8 or day 13, we expect to see 
different transcription factors than those found in earlier stages of development.  For the 
most part, immature NK cells have been found to express Gata-3, T-bet, and IRF-2, 
whereas mature NK cells express CEBP-, MEF, and MITF [13].  Gata-3 is has been 
shown to be necessary for the proper expression of CD11b, CD43, and Ly49s on NK 
cells along with CD127 on thymic NK cells [97].  It has been found to have a 
contradictory function in NK cells compared to T cells, promoting IFN- production by 
mature NK cells [97].  In addition, Gata-3 has been associated with T-bet, which has 
similar affects on CD11b and CD43 expression [98].  NK cells that develop in the 
absence of T-bet have comparable cytotoxicity as their normal counterparts, but are 
unable produce INF after stimulation.  A study done by Taki and colleagues shows that 
IRF-2 also plays an important role in NK cell development in the BM and is also required 
for proper CD11b and CD43 expression [99].  Results also show that mice deficient in 
IRF-2 had a reduced number of splenic NK cells that had an immature phenotype, 
lacking DX5 and Ly49 expression as well as expressing low levels of CD11b and CD43.  
This study also found that although these cells seemed immature, they were found to 
have normal cytotoxicity against sensitive targets.  While we expect to see GATA-3 and 
T-bet gene up-regulation, we suspect IRF-2 will not be detectable.   
 Unlike TFs involved in immature NK cells, TFs in mature NK cells are important 
for proper effector functions.  While an absence of CEBP-, MEF, and MITF in these 
cells has been shown to not have a negative impact on development and differentiation, 
this deficiency has been implicated in a reduction of cytotoxicity and cytokine production 
[13].  The absence of these TFs leads to a reduction in perforin and granzyme expression, 
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both of which are necessary to carry out an appropriate effector function [13].  Since our 
results suggest the in vitro generated NK cells are functional, we suspect these TFs will 
be expressed.   
 By using the gene profiling method, we will be able to take a closer look at the 
TFs that are involved in the developmental process.  Because most of these TFs were 
shown to be expressed during BM development, we expect to find some differences.  
While we have initiated the process by doing the microarray, further studies that will 
verify these results, such as quantitative RT-PCR, are still pending.          
 
Determine whether NK cells in the GALT are derived from thymic DN1 CD122
-
NK1.1
-
 progenitors  
 Human and mouse studies have shown that different NK subsets are present 
within the gut-associated lymphoid tissue (GALT) including the intraepithelial lymphoid 
compartment, intestinal lamina propria, Peyer's patches, and mesenteric lymphoid nodes 
[100, 101].  Analysis of NK cells found within the intestinal mucosa revealed the 
presence of a unique subpopulation that was NKp46
+
CD127
+
Ly49
-
NK1.1
+/-
, along with a 
second population that resembled conventional NK cells [102].  While very little is 
known about their receptor repertoire and effector function, the developmental origin of 
these cells has yet to be determined. 
 To assess whether the NKp46
+
CD127
+
Ly49
-
NK1.1
+
 cells are thymic-derived NK 
cells, we will repeat the adoptive transfer experiments but expand our search for the 
donor-differentiated NK cells.  Briefly, DN1 CD122
-
NK1.1
-
 thymic progenitors from 
Rag1
-/-
Ly5.2 mice will be enriched via FACS sorting.  These cells will be intrathymically 
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injected into irradiated congenic Rag1
-/-
Ly5.1 mice.  Based on our previous results, cells 
will be allowed to differentiate in vivo for 35-45 days, at which point, we will harvest 
spleen, thymus, lungs, small intestine, and large intestine.  We will look for the presence 
of Ly5.2
+
 NK cells by staining with both anti-NK1.1 and anti-NKp46 antibodies.  To 
further characterize these cells, we will look at their phenotypic profile by staining the 
previously described surface molecules. 
    Taking our recent CD103 discovery into consideration, we expect to find Ly5.2
+
 
NK cells in mucosal tissues.  Whether these cells are NKp46
+
NK1.1
-
 or NKp46
+
NK1.1
+
 
will be further investigated upon phenotypic analysis.  Positive results will suggest that 
the DN1 CD122
-
NK1.1
-
 progenitors differentiate in the thymus, then guided by the 
CD103 integrin, along with some other unknown factors, emigrate from the thymus and 
homes to mucosal tissues.  We can speculate that CD103 is involved in the thymic NK 
cell migration since our results showed an increase in numbers of CD127
+
 NK cells in the 
thymus of CD103
-/-
 mice.  Further validation as to whether it is directly involved in 
homing to mucosal tissues would need to be done by assessing the presence or absence of 
these cells in the lungs or intestinal mucosa of CD103
-/-
 mice.  However, negative results 
may suggest a number of things:  1)  The presence of Ly5.2
+
CD127
-
 NK cells, with a 
similar thymic phenotype could suggest these cells developed in the thymus, but upon 
homing to the tissue, altered their phenotype to better suit the environment.  2)  The 
presence of Ly5.2
-
CD127
+ 
NK cells would indicate these cells are not the same subset as 
those derived from the thymus.  Together, these future studies will perhaps provide an 
insight as to whether thymic NK cells have a specific role in not only the thymus, but in 
the mucosal tissues as well. 
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Do thymic NK cells carry out a specific function 
 NK cells are often thought of as killing machines that zone in on a target, bind, 
and lyse all within a matter of minutes.  The discovery of NK subsets has shown this to 
be an erroneous idea.  Since NK cells can circulate in the blood and are found in 
secondary lymphoid tissue and non-lymphoid tissue, they may have a role in systemic 
immunosurveillance against various pathogens and tumors [103].  However, studies have 
shown that a subset of uterine NK cells in both humans and mice contribute and sustain 
important changes in the maternal placental bed during the first half of gestation, mainly 
by secreting vascular endothelial growth factor (VEGF) [104].   
 In addition, the mucosal NK subset, termed NK-22, that was recently described 
has been shown to express both IL22 transcripts and proteins [58, 105].  IL22, which 
belongs to the IL10 family of cytokines, has been shown to protects the epithelial cell 
barrier in the gut and other mucosal tissues from pathogens [106, 107].  Unlike 
conventional NK cells that carry out their function by detecting targets cells that have 
down-regulated their MHC [108], these mucosal NK cells are highly responsive to IL23 
in both human and mouse [58].  Studies have shown this NK-22 subset provides a 
protective barrier against intestinal C. rodentium infection in Rag2
-/-
 mice [109].  Perhaps 
the tolerogenic effect that both uterine and intestinal NK cells have, may provide the 
clues necessary to determine the specific effector function of thymic NK cells.   
 Once we determine whether thymus-derived NK cells have the potential to home 
to the gut, we can further study their effector function by applying some of the same 
methods described above.  Since studies showed that  Rag KO mice are resistant to C. 
rodentium infection due to NK cells in the mucosa, we can utilize Rag1
-/c
-/-
 mice to 
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address specific function.  Due to their lack of T, B, and NK cells, we suspect these mice 
will succumb to the infection.  Once this has been established, we can adoptively transfer 
CD127
+
 NK cells and assess the mice for weight loss and survival.  Studies examining 
the role of naive CD4
+
CD45RB
hi
 T cells in irritable bowel syndrome suggest 
approximately 5x10
5
 cells is an appropriate number to see any type of results, therefore, 
we will start with this number of CD127
+ 
NK cells and transfer them IP.  These studies 
could result in two possible outcomes:  1)  The mice will survive, suggesting that CD127
+ 
NK cells have a tolerogenic role.  2)  The mice will succumb to infection, suggesting 
either that CD127
+
 NK cells are not responsible for repopulating the mucosa, thus 
providing no source of protection, or that they need the presence of other NK subsets to 
effectively protect the mice.  
 While this is only one source of infection, we could repeat these experiments 
using a several KO mice including the IL7
-/-
 and CD103
-/-
, in addition to us depleting the 
cells with specific antibodies.  Furthermore, we could infect mice with a number of 
different pathogens and, once again, assess the phenotype and function of 
CD127
+
CD103
+
NK cells present in the thymus and perhaps in the intestinal mucosa as 
well.  Taken together, these studies will allow us to further examine the potential role of 
thymic NK cells during a pathogen infection.  However, it is essential that we first 
determine whether these NK cells are permanent residence of the thymus, or whether 
they have the potential to home to other tissues.     
 
133 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
 
 
 
 
134 
 
1. Yokoyama, W.M., Natural Killer Cells, in Fundamental Immunology, W.E. Paul, 
Editor. 2008, Lippincott Williams & Wilkins. 
2. Martin-Fontecha, A., et al., Induced recruitment of NK cells to lymph nodes 
provides IFN-gamma for T(H)1 priming. Nat Immunol, 2004. 5(12): p. 1260-5. 
3. Shi, F.D., et al., Natural killer cells determine the outcome of B cell-mediated 
autoimmunity. Nat Immunol, 2000. 1(3): p. 245-51. 
4. Trinchieri, G., Biology of natural killer cells. Adv Immunol, 1989. 47: p. 187-376. 
5. Murphy, K., Travers, P., Walport, M., Innate Immunity, in Immunobiology: the 
immune system in health and disease. 2008, Garland Science Publishing. 
6. Smyth, M.J., et al., Activation of NK cell cytotoxicity. Mol Immunol, 2005. 42(4): 
p. 501-10. 
7. Arase, H., N. Arase, and T. Saito, Interferon gamma production by natural killer 
(NK) cells and NK1.1+ T cells upon NKR-P1 cross-linking. J Exp Med, 1996. 
183(5): p. 2391-6. 
8. Yokoyama, W.M., S. Kim, and A.R. French, The dynamic life of natural killer 
cells. Annu Rev Immunol, 2004. 22: p. 405-29. 
9. Loh, J., et al., Natural killer cells utilize both perforin and gamma interferon to 
regulate murine cytomegalovirus infection in the spleen and liver. J Virol, 2005. 
79(1): p. 661-7. 
10. Dorshkind, K., et al., Natural killer (NK) cells are present in mice with severe 
combined immunodeficiency (scid). J Immunol, 1985. 134(6): p. 3798-801. 
11. Mombaerts, P., et al., RAG-1-deficient mice have no mature B and T lymphocytes. 
Cell, 1992. 68(5): p. 869-77. 
12. Shinkai, Y., et al., RAG-2-deficient mice lack mature lymphocytes owing to 
inability to initiate V(D)J rearrangement. Cell, 1992. 68(5): p. 855-67. 
13. Di Santo, J.P., Natural killer cell developmental pathways: a question of balance. 
Annu Rev Immunol, 2006. 24: p. 257-86. 
14. Igarashi, H., et al., Transcription from the RAG1 locus marks the earliest 
lymphocyte progenitors in bone marrow. Immunity, 2002. 17(2): p. 117-30. 
15. Kondo, M., I.L. Weissman, and K. Akashi, Identification of clonogenic common 
lymphoid progenitors in mouse bone marrow. Cell, 1997. 91(5): p. 661-72. 
16. Rosmaraki, E.E., et al., Identification of committed NK cell progenitors in adult 
murine bone marrow. Eur J Immunol, 2001. 31(6): p. 1900-9. 
17. Waldmann, T.A. and Y. Tagaya, The multifaceted regulation of interleukin-15 
expression and the role of this cytokine in NK cell differentiation and host 
response to intracellular pathogens. Annu Rev Immunol, 1999. 17: p. 19-49. 
18. Vosshenrich, C.A., et al., Roles for common cytokine receptor gamma-chain-
dependent cytokines in the generation, differentiation, and maturation of NK cell 
precursors and peripheral NK cells in vivo. J Immunol, 2005. 174(3): p. 1213-21. 
19. Iizuka, K., et al., Requirement for membrane lymphotoxin in natural killer cell 
development. Proc Natl Acad Sci U S A, 1999. 96(11): p. 6336-40. 
20. Kim, S., et al., In vivo developmental stages in murine natural killer cell 
maturation. Nat Immunol, 2002. 3(6): p. 523-8. 
135 
 
21. Sivakumar, P.V., et al., Cutting edge: expression of functional CD94/NKG2A 
inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of 
tolerance during NK cell development. J Immunol, 1999. 162(12): p. 6976-80. 
22. Williams, N.S., et al., Generation of lytic natural killer 1.1+, Ly-49- cells from 
multipotential murine bone marrow progenitors in a stroma-free culture: 
definition of cytokine requirements and developmental intermediates. J Exp Med, 
1997. 186(9): p. 1609-14. 
23. Williams, N.S., et al., Differentiation of NK1.1+, Ly49+ NK cells from flt3+ 
multipotent marrow progenitor cells. J Immunol, 1999. 163(5): p. 2648-56. 
24. Roth, C., et al., Clonal acquisition of inhibitory Ly49 receptors on developing NK 
cells is successively restricted and regulated by stromal class I MHC. Immunity, 
2000. 13(1): p. 143-53. 
25. Williams, N.S., et al., Clonal analysis of NK cell development from bone marrow 
progenitors in vitro: orderly acquisition of receptor gene expression. Eur J 
Immunol, 2000. 30(7): p. 2074-82. 
26. Nakano, T., H. Kodama, and T. Honjo, Generation of lymphohematopoietic cells 
from embryonic stem cells in culture. Science, 1994. 265(5175): p. 1098-101. 
27. Rodewald, H.R., et al., A population of early fetal thymocytes expressing Fc 
gamma RII/III contains precursors of T lymphocytes and natural killer cells. Cell, 
1992. 69(1): p. 139-50. 
28. Carlyle, J.R., et al., Identification of a novel developmental stage marking lineage 
commitment of progenitor thymocytes. J Exp Med, 1997. 186(2): p. 173-82. 
29. Ikawa, T., et al., Commitment of common T/Natural killer (NK) progenitors to 
unipotent T and NK progenitors in the murine fetal thymus revealed by a single 
progenitor assay. J Exp Med, 1999. 190(11): p. 1617-26. 
30. Douagi, I., et al., Identification of the earliest prethymic bipotent T/NK progenitor 
in murine fetal liver. Blood, 2002. 99(2): p. 463-71. 
31. Jaleco, A.C., et al., Fetal liver contains committed NK progenitors, but is not a 
site for development of CD34+ cells into T cells. J Immunol, 1997. 159(2): p. 
694-702. 
32. Carlyle, J.R. and J.C. Zuniga-Pflucker, Requirement for the thymus in alphabeta T 
lymphocyte lineage commitment. Immunity, 1998. 9(2): p. 187-97. 
33. Porritt, H.E., et al., Heterogeneity among DN1 prothymocytes reveals multiple 
progenitors with different capacities to generate T cell and non-T cell lineages. 
Immunity, 2004. 20(6): p. 735-45. 
34. Freud, A.G., et al., A human CD34(+) subset resides in lymph nodes and 
differentiates into CD56bright natural killer cells. Immunity, 2005. 22(3): p. 295-
304. 
35. Takeda, K., et al., TRAIL identifies immature natural killer cells in newborn mice 
and adult mouse liver. Blood, 2005. 105(5): p. 2082-9. 
36. Di Santo, J.P. and C.A. Vosshenrich, Bone marrow versus thymic pathways of 
natural killer cell development. Immunol Rev, 2006. 214: p. 35-46. 
37. Manaster, I. and O. Mandelboim, The unique properties of uterine NK cells. Am J 
Reprod Immunol, 2010. 63(6): p. 434-44. 
136 
 
38. Yadi, H., et al., Unique receptor repertoire in mouse uterine NK cells. J Immunol, 
2008. 181(9): p. 6140-7. 
39. Vosshenrich, C.A., et al., A thymic pathway of mouse natural killer cell 
development characterized by expression of GATA-3 and CD127. Nat Immunol, 
2006. 7(11): p. 1217-24. 
40. Kaech, S.M., et al., Selective expression of the interleukin 7 receptor identifies 
effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol, 
2003. 4(12): p. 1191-8. 
41. Fry, T.J. and C.L. Mackall, Interleukin-7: from bench to clinic. Blood, 2002. 
99(11): p. 3892-904. 
42. Puel, A. and W.J. Leonard, Mutations in the gene for the IL-7 receptor result in 
T(-)B(+)NK(+) severe combined immunodeficiency disease. Curr Opin Immunol, 
2000. 12(4): p. 468-73. 
43. Ribeiro, V.S., et al., Cutting edge: Thymic NK cells develop independently from T 
cell precursors. J Immunol, 2010. 185(9): p. 4993-7. 
44. Prlic, M., et al., In vivo survival and homeostatic proliferation of natural killer 
cells. J Exp Med, 2003. 197(8): p. 967-76. 
45. Cooper, M.A., et al., In vivo evidence for a dependence on interleukin 15 for 
survival of natural killer cells. Blood, 2002. 100(10): p. 3633-8. 
46. Ranson, T., et al., IL-15 is an essential mediator of peripheral NK-cell 
homeostasis. Blood, 2003. 101(12): p. 4887-93. 
47. Maroof, A., et al., Posttranscriptional regulation of II10 gene expression allows 
natural killer cells to express immunoregulatory function. Immunity, 2008. 29(2): 
p. 295-305. 
48. Hansson, M., et al., Natural NK-cell targets in the mouse thymus: characteristics 
of the sensitive cell population. J Immunol, 1979. 123(2): p. 765-71. 
49. Freud, A.G. and M.A. Caligiuri, Human natural killer cell development. Immunol 
Rev, 2006. 214: p. 56-72. 
50. Cooper, M.A., T.A. Fehniger, and M.A. Caligiuri, The biology of human natural 
killer-cell subsets. Trends Immunol, 2001. 22(11): p. 633-40. 
51. Fehniger, T.A., et al., CD56bright natural killer cells are present in human lymph 
nodes and are activated by T cell-derived IL-2: a potential new link between 
adaptive and innate immunity. Blood, 2003. 101(8): p. 3052-7. 
52. Chan, A., et al., CD56bright human NK cells differentiate into CD56dim cells: 
role of contact with peripheral fibroblasts. J Immunol, 2007. 179(1): p. 89-94. 
53. Cooper, M.A., et al., Human natural killer cells: a unique innate 
immunoregulatory role for the CD56(bright) subset. Blood, 2001. 97(10): p. 
3146-51. 
54. Idris, A.H., et al., The natural killer gene complex genetic locus Chok encodes Ly-
49D, a target recognition receptor that activates natural killing. Proc Natl Acad 
Sci U S A, 1999. 96(11): p. 6330-5. 
55. Cheng, M., et al., Distinct and overlapping patterns of cytokine regulation of 
thymic and bone marrow-derived NK cell development. J Immunol, 2009. 182(3): 
p. 1460-8. 
137 
 
56. Sjostrom, A., et al., Acquisition of external major histocompatibility complex 
class I molecules by natural killer cells expressing inhibitory Ly49 receptors. J 
Exp Med, 2001. 194(10): p. 1519-30. 
57. Jonsson, A.H. and W.M. Yokoyama, Natural killer cell tolerance licensing and 
other mechanisms. Adv Immunol, 2009. 101: p. 27-79. 
58. Cella, M., et al., A human natural killer cell subset provides an innate source of 
IL-22 for mucosal immunity. Nature, 2009. 457(7230): p. 722-5. 
59. Agace, W.W., et al., T-lymphocyte-epithelial-cell interactions: integrin 
alpha(E)(CD103)beta(7), LEEP-CAM and chemokines. Curr Opin Cell Biol, 
2000. 12(5): p. 563-8. 
60. Kilshaw, P.J. and S.J. Murant, Expression and regulation of beta 7(beta p) 
integrins on mouse lymphocytes: relevance to the mucosal immune system. Eur J 
Immunol, 1991. 21(10): p. 2591-7. 
61. Affymetrix. GeneChip Mouse Genome 430 2.0 Array.  2011  [cited 2011 June]; 
Available from: 
http://www.affymetrix.com/estore/browse/products.jsp;jsessionid=72E4DB0B103
C7E75B0EA3DCF2175DB3D?navMode=34000&productId=131477&navAction
=jump&aId=productsNav#1_1. 
62. Bots, M. and J.P. Medema, Granzymes at a glance. J Cell Sci, 2006. 119(Pt 24): 
p. 5011-4. 
63. Allen, M.P. and M. Nilsen-Hamilton, Granzymes D, E, F, and G are regulated 
through pregnancy and by IL-2 and IL-15 in granulated metrial gland cells. J 
Immunol, 1998. 161(6): p. 2772-9. 
64. Cerf-Bensussan, N., et al., A monoclonal antibody (HML-1) defining a novel 
membrane molecule present on human intestinal lymphocytes. Eur J Immunol, 
1987. 17(9): p. 1279-85. 
65. Russell, G.J., et al., Distinct structural and functional epitopes of the alpha E beta 
7 integrin. Eur J Immunol, 1994. 24(11): p. 2832-41. 
66. Kilshaw, P.J. and S.J. Murant, A new surface antigen on intraepithelial 
lymphocytes in the intestine. Eur J Immunol, 1990. 20(10): p. 2201-7. 
67. del Rio, M.L., et al., CD103- and CD103+ bronchial lymph node dendritic cells 
are specialized in presenting and cross-presenting innocuous antigen to CD4+ 
and CD8+ T cells. J Immunol, 2007. 178(11): p. 6861-6. 
68. Butcher, E.C., et al., Lymphocyte trafficking and regional immunity. Adv 
Immunol, 1999. 72: p. 209-53. 
69. Cepek, K.L., et al., Adhesion between epithelial cells and T lymphocytes mediated 
by E-cadherin and the alpha E beta 7 integrin. Nature, 1994. 372(6502): p. 190-3. 
70. Karecla, P.I., et al., Recognition of E-cadherin on epithelial cells by the mucosal T 
cell integrin alpha M290 beta 7 (alpha E beta 7). Eur J Immunol, 1995. 25(3): p. 
852-6. 
71. Brown, D.W., et al., Mechanisms of binding of cutaneous lymphocyte-associated 
antigen-positive and alphaebeta7-positive lymphocytes to oral and skin 
keratinocytes. Immunology, 1999. 98(1): p. 9-15. 
72. Cepek, K.L., et al., Integrin alpha E beta 7 mediates adhesion of T lymphocytes to 
epithelial cells. J Immunol, 1993. 150(8 Pt 1): p. 3459-70. 
138 
 
73. Roberts, A.I., S.M. O'Connell, and E.C. Ebert, Intestinal intraepithelial 
lymphocytes bind to colon cancer cells by HML-1 and CD11a. Cancer Res, 1993. 
53(7): p. 1608-11. 
74. Schon, M.P., et al., Mucosal T lymphocyte numbers are selectively reduced in 
integrin alpha E (CD103)-deficient mice. J Immunol, 1999. 162(11): p. 6641-9. 
75. Nozad Charoudeh, H., et al., Identification of an NK/T cell-restricted progenitor 
in adult bone marrow contributing to bone marrow- and thymic-dependent NK 
cells. Blood, 2010. 116(2): p. 183-92. 
76. Pudney, J. and D.J. Anderson, Immunobiology of the human penile urethra. Am J 
Pathol, 1995. 147(1): p. 155-65. 
77. Christmas, S.E., et al., T-cell receptor heterogeneity of gamma delta T-cell clones 
from human female reproductive tissues. Immunology, 1993. 78(3): p. 436-43. 
78. Erle, D.J., et al., Lung epithelial lining fluid T cell subsets defined by distinct 
patterns of beta 7 and beta 1 integrin expression. Am J Respir Cell Mol Biol, 
1994. 10(3): p. 237-44. 
79. Lohmeyer, J., et al., Expression of mucosa-related integrin alphaEbeta7 on 
alveolar T cells in interstitial lung diseases. Clin Exp Immunol, 1999. 116(2): p. 
340-6. 
80. Palmer, M.J., et al., Interleukin-7 receptor signaling network: an integrated 
systems perspective. Cell Mol Immunol, 2008. 5(2): p. 79-89. 
81. Park, J.H., et al., Suppression of IL7Ralpha transcription by IL-7 and other 
prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell 
survival. Immunity, 2004. 21(2): p. 289-302. 
82. Blattman, J.N., et al., Estimating the precursor frequency of naive antigen-specific 
CD8 T cells. J Exp Med, 2002. 195(5): p. 657-64. 
83. Munitic, I., et al., Dynamic regulation of IL-7 receptor expression is required for 
normal thymopoiesis. Blood, 2004. 104(13): p. 4165-72. 
84. Ceredig, R. and T. Rolink, A positive look at double-negative thymocytes. Nat 
Rev Immunol, 2002. 2(11): p. 888-97. 
85. Godfrey, D.I., A. Zlotnik, and T. Suda, Phenotypic and functional 
characterization of c-kit expression during intrathymic T cell development. J 
Immunol, 1992. 149(7): p. 2281-5. 
86. Moore, K.A., H. Ema, and I.R. Lemischka, In vitro maintenance of highly 
purified, transplantable hematopoietic stem cells. Blood, 1997. 89(12): p. 4337-
47. 
87. Scott, E.W., et al., PU.1 functions in a cell-autonomous manner to control the 
differentiation of multipotential lymphoid-myeloid progenitors. Immunity, 1997. 
6(4): p. 437-47. 
88. DeKoter, R.P. and H. Singh, Regulation of B lymphocyte and macrophage 
development by graded expression of PU.1. Science, 2000. 288(5470): p. 1439-
41. 
89. DeKoter, R.P., H.J. Lee, and H. Singh, PU.1 regulates expression of the 
interleukin-7 receptor in lymphoid progenitors. Immunity, 2002. 16(2): p. 297-
309. 
139 
 
90. Colucci, F., et al., Differential requirement for the transcription factor PU.1 in the 
generation of natural killer cells versus B and T cells. Blood, 2001. 97(9): p. 
2625-32. 
91. Barton, K., et al., The Ets-1 transcription factor is required for the development of 
natural killer cells in mice. Immunity, 1998. 9(4): p. 555-63. 
92. Georgopoulos, K., et al., The Ikaros gene is required for the development of all 
lymphoid lineages. Cell, 1994. 79(1): p. 143-56. 
93. Wang, J.H., et al., Selective defects in the development of the fetal and adult 
lymphoid system in mice with an Ikaros null mutation. Immunity, 1996. 5(6): p. 
537-49. 
94. Boggs, S.S., et al., Lack of natural killer cell precursors in fetal liver of Ikaros 
knockout mutant mice. Nat Immun, 1998. 16(4): p. 137-45. 
95. Heemskerk, M.H., et al., Inhibition of T cell and promotion of natural killer cell 
development by the dominant negative helix loop helix factor Id3. J Exp Med, 
1997. 186(9): p. 1597-602. 
96. Ikawa, T., et al., Commitment to natural killer cells requires the helix-loop-helix 
inhibitor Id2. Proc Natl Acad Sci U S A, 2001. 98(9): p. 5164-9. 
97. Samson, S.I., et al., GATA-3 promotes maturation, IFN-gamma production, and 
liver-specific homing of NK cells. Immunity, 2003. 19(5): p. 701-11. 
98. Townsend, M.J., et al., T-bet regulates the terminal maturation and homeostasis 
of NK and Valpha14i NKT cells. Immunity, 2004. 20(4): p. 477-94. 
99. Taki, S., et al., IFN regulatory factor-2 deficiency revealed a novel checkpoint 
critical for the generation of peripheral NK cells. J Immunol, 2005. 174(10): p. 
6005-12. 
100. Sanos, S.L. and A. Diefenbach, Isolation of NK cells and NK-like cells from the 
intestinal lamina propria. Methods Mol Biol, 2010. 612: p. 505-17. 
101. Leon, F., et al., Human small-intestinal epithelium contains functional natural 
killer lymphocytes. Gastroenterology, 2003. 125(2): p. 345-56. 
102. Colonna, M., Interleukin-22-producing natural killer cells and lymphoid tissue 
inducer-like cells in mucosal immunity. Immunity, 2009. 31(1): p. 15-23. 
103. Gregoire, C., et al., The trafficking of natural killer cells. Immunol Rev, 2007. 
220: p. 169-82. 
104. Croy, B.A., et al., Update on pathways regulating the activation of uterine 
Natural Killer cells, their interactions with decidual spiral arteries and homing of 
their precursors to the uterus. J Reprod Immunol, 2003. 59(2): p. 175-91. 
105. Luci, C., et al., Influence of the transcription factor RORgammat on the 
development of NKp46+ cell populations in gut and skin. Nat Immunol, 2009. 
10(1): p. 75-82. 
106. Aujla, S.J. and J.K. Kolls, IL-22: a critical mediator in mucosal host defense. J 
Mol Med, 2009. 87(5): p. 451-4. 
107. Kotenko, S.V., The family of IL-10-related cytokines and their receptors: related, 
but to what extent? Cytokine Growth Factor Rev, 2002. 13(3): p. 223-40. 
108. Yokoyama, W.M., Natural killer cell immune responses. Immunol Res, 2005. 
32(1-3): p. 317-25. 
140 
 
109. Zheng, Y., et al., Interleukin-22 mediates early host defense against attaching and 
effacing bacterial pathogens. Nat Med, 2008. 14(3): p. 282-9. 
 
 
